Publications

• Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
  Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., … Fowler, N. H. (2013). Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies. JOURNAL OF CLINICAL ONCOLOGY, 31(1), 88–94.
• A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance
  Advani, R., Fisher, G. A., Lum, B. L., Hausdorff, J., Halsey, J., Litchman, M., & Sikic, B. I. (2001). A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. CLINICAL CANCER RESEARCH, 7(5), 1221–29.
• PHASE 1 STUDY OF NAVITOCLAX (ABT-263) PLUS RITUXIMAB IN CD20-POSITIVE LYMPHOID MALIGNANCIES
  Roberts, W., Advani, R., Kahl, B., Persky, D., Xiong, H., Cui, Y., … Humerickhouse, R. (2010). PHASE 1 STUDY OF NAVITOCLAX (ABT-263) PLUS RITUXIMAB IN CD20-POSITIVE LYMPHOID MALIGNANCIES. Presented at the 15th Annual Meeting of the European-Hematology-Association, BARCELONA,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN,SPAIN: FERRATA STORTI FOUNDATION.
• Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy Advani, R., Rosenberg, S. A., & Horning, S. J. (2004). Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy. JOURNAL OF CLINICAL ONCOLOGY, 22(8), 1454–59.
  
• Risk stratification in extranodal natural killer/T-cell lymphoma Kohrt, H., Lee, M., & Advani, R. (2010). Risk stratification in extranodal natural killer/T-cell lymphoma. EXPERT REVIEW OF ANTICANCER THERAPY, 10(9), 1395–1405.
  
• Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results Brody, J. D., Czerwinski, D. K., Carlton, V., Moorhead, M., Zheng, J., Klinger, M., … Levy, R. (2011). Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results. BLOOD, 118(21), 1323–23.
  
• Staging accuracy in mycosis fungoides and Sezary syndrome using integrated positron emission tomography and computed tomography Tsai, E. Y., Taur, A., Espinosa, L., Quon, A., Johnson, D., Dick, S., … Kim, Y. H. (2006). Staging accuracy in mycosis fungoides and Sezary syndrome using integrated positron emission tomography and computed tomography. ARCHIVES OF DERMATOLOGY, 142(5), 577–84.
  
• A Phase 1/2A Open-Label Study of Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lympboprolifierative Malignancies Horwitz, S. M., Vose, J. M., Advani, R., Sankhala, K., Padmanabhan, S., Hamlin, P. A., … O'Connor, O. A. (2008). A Phase 1/2A Open-Label Study of Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lympboprolifierative Malignancies. BLOOD, 112(11), 557–57.
  
• A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Geary, R. S., Holmlund, J. T., … Sikic, B. I. (2005). A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. INVESTIGATIONAL NEW DRUGS, 23(5), 467–77.
  
• Optimal therapy of advanced Hodgkin lymphoma. Advani, R. (2011). Optimal therapy of advanced Hodgkin lymphoma. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2011, 310–16.
  
• The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial Wang, L., Martin, P., Blum, K. A., Kahl, B. S., Maeda, L. S., Advani, R., … Goy, A. (2011). The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial. BLOOD, 118(21), 203–4.
  
• PHASE II STUDY OF R-CHOP FOLLOWED BY Y-90-IBRITUMOMAB TIUXETAN IN UNTREATED MANTLE CELL LYMPHOMA (MCL): 5 YEAR FOLLOW-UP OF EASTERN COOPERATIVE ONCOLOGY GROUP E1499 Smith, M. R., Li, H., Gordon, L., Gascoyne, R., Paietta, E., Forero-Torres, A., … Horning, S. (2011). PHASE II STUDY OF R-CHOP FOLLOWED BY Y-90-IBRITUMOMAB TIUXETAN IN UNTREATED MANTLE CELL LYMPHOMA (MCL): 5 YEAR FOLLOW-UP OF EASTERN COOPERATIVE ONCOLOGY GROUP E1499. Presented at the 11th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND: OXFORD UNIV PRESS.
  
• Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies Advani, R., Fisher, G. A., Lum, B. L., Jambalos, C., Cho, C. D., Cohen, M., … Sikic, B. I. (2003). Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. CLINICAL CANCER RESEARCH, 9(14), 5187–94.
  
• Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Results of a phase II trial of intra-tumoral CPG-[PF-3512676] Brody, J. D., Ai, W. Z., Czerwinski, D. K., Advani, R., Horning, S. J., Hoppe, R. T., & Levy, R. (2008). Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Results of a phase II trial of intra-tumoral CPG-[PF-3512676]. Presented at the 10th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND: OXFORD UNIV PRESS.
  
• Lymphoma in Pregnancy Initially Diagnosed as Vaginal Intraepithelial Neoplasia and Lichen Planus Thuong-Thuong Nguyen, T. T., Gubens, M., Arber, D. A., Advani, R., Juretzka, M., & Aziz, N. (2011). Lymphoma in Pregnancy Initially Diagnosed as Vaginal Intraepithelial Neoplasia and Lichen Planus. OBSTETRICS AND GYNECOLOGY, 118(2), 486–89.
  
• MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP Alencar, A. J., Malumbres, R., Kozloski, G. A., Advani, R., Talreja, N., Chinichian, S., … Lossos, I. S. (2011). MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP. CLINICAL CANCER RESEARCH, 17(12), 4125–35.
  
• Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines Powell, A. A., Talasaz, A. A. H., Zhang, H., Coram, M. A., Reddy, A., Deng, G., … Jeffrey, S. S. (2012). Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines. PLOS ONE, 7(5).
  
• A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML) Pollyea, D. A., Kohrt, H. E., Gallegos, L., Berube, C., Coutre, S., Gotlib, J., … Medeiros, B. C. (2010). A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML). BLOOD, 116(21), 1347–47.
  
• Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Kanakry, J. A., Li, H., Gellert, L. L., Lemas, M. V., Hsieh, W.-S., Hong, F., … Ambinder, R. F. (2013). Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood, 121(18), 3547–53.
  
• Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma Advani, R., Forero-Torres, A., Furman, R. R., Rosenblatt, J. D., Younes, A., Ren, H., … Drachman, J. G. (2009). Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 27(26), 4371–77.
  
• CD81 Protein Is Expressed in Normal Germinal Center B-Cells and in Subtypes of Human Non-Hodgkin Lymphomas Luo, R. F., Zhao, S., Tibshirani, R., Lossos, I. S., Advani, R., Gratzinger, D., … Natkunam, Y. (2009). CD81 Protein Is Expressed in Normal Germinal Center B-Cells and in Subtypes of Human Non-Hodgkin Lymphomas. Presented at the 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, BOSTON,MA,MA,MA,MA,MA,MA,MA,MA: NATURE PUBLISHING GROUP.
  
• Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial Advani, R. H., Hoppe, R. T., Baer, D., Mason, J., Warnke, R., Allen, J., … Horning, S. J. (2013). Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. ANNALS OF ONCOLOGY, 24(4), 1044–48.
  
• A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. Cho, C. D., Fisher, G. A., Halsey, J., Jambalos, C. N., Schwartz, E. J., Rouse, R. V., … Sikic, B. I. (2003). A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. CLINICAL CANCER RESEARCH, 9(16), 6103S–6103S.
  
• Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP) Gratzinger, D., Advani, R., Zhao, S., Talreja, N., Tibshirani, R. J., Horning, S. J., … Natkunam, Y. (2009). Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP). JOURNAL OF CLINICAL ONCOLOGY, 27(15).
  
• In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study Kim, Y. H., Gratzinger, D., Harrison, C., Brody, J. D., Czerwinski, D. K., Ai, W. Z., … Levy, R. (2012). In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. BLOOD, 119(2), 355–63.
  
• STAGE I-IIIA NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS USEFUL? THE STANFORD EXPERIENCE Advani, R. H., Hoppe, R. T., Maeda, L. S., Baer, D. M., Mason, J., Rosenberg, S. A., & Horning, S. J. (2011). STAGE I-IIIA NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS USEFUL? THE STANFORD EXPERIENCE. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(5), 1374–79.
  
• Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development. Chen, A. I., & Advani, R. H. (2008). Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development. Journal of the National Comprehensive Cancer Network , 6(4), 428–35.
  
• Non-Hodgkin lymphoma of the breast Ganjoo, K., Advani, R., Mariappan, M. R., McMillan, A., & Horning, S. (2007). Non-Hodgkin lymphoma of the breast. CANCER, 110(1), 25–30.
  
• Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995) Greenberg, P. L., Lee, S. J., Advani, R., Tallman, M. S., Sikic, B. I., Letendre, L., … Rowe, J. M. (2004). Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995). JOURNAL OF CLINICAL ONCOLOGY, 22(6), 1078–86.
  
• A Phase I Trial of Aprinocarsen (ISIS 3521/LY900003), an Antisense Inhibitor of Protein Kinase C-alpha Administered as a 24-hour Weekly Infusion Schedule in Patients with Advanced Cancer. A Phase I Trial of Aprinocarsen (ISIS 3521/LY900003), an Antisense Inhibitor of Protein Kinase C-alpha Administered as a 24-hour Weekly Infusion Schedule in Patients with Advanced Cancer. (2005). Investigational New Drugs, In Press.
  
• Dynamic CD8 T-Cell Responses to Tumor-Associated Epstein-Barr Virus Antigens in Patients With Epstein-Barr Virus-Negative Hodgkin's Disease Kohrt, H., Johannsen, A., Hoppe, R., Horning, S. J., Rosenberg, S. A., Advani, R., & Lee, P. P. (2009). Dynamic CD8 T-Cell Responses to Tumor-Associated Epstein-Barr Virus Antigens in Patients With Epstein-Barr Virus-Negative Hodgkin's Disease. ONCOLOGY RESEARCH, 18(5-6), 287–92.
  
• PET status after Stanford V chemotherapy predicts outcome in Hodgkins disease Advani, R., Maeda, L., Lavori, P., Hoppe, R., Breslin, S., Rosenberg, S., & Horning, S. (2005). PET status after Stanford V chemotherapy predicts outcome in Hodgkins disease. Presented at the 9th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND: OXFORD UNIV PRESS.
  
• Sezary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC) Olsen, E. A., Rook, A. H., Zic, J., Kim, Y., Porcu, P., Querfeld, C., … Duvic, M. (2011). Sezary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 64(2), 352–404.
  
• Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Liu, C. L., Kohrt, H. E., Houot, R., … Levy, R. (2011). Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. BLOOD, 118(5), 1350–58.
  
• The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma Maeda, L. S., & Advani, R. H. (2009). The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma. CURRENT OPINION IN ONCOLOGY, 21(5), 397–400.
  
• Treatment of mantle cell lymphoma: Current approach and future directions Brody, J., & Advani, R. (2006). Treatment of mantle cell lymphoma: Current approach and future directions. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 58(3), 257–65.
  
• Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study Horning, S. J., Juweid, M. E., Schoeder, H., Wiseman, G., McMillan, A., Swinnen, L. J., … Quon, A. (2010). Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. BLOOD, 115(4), 775–77.
  
• Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, R., Goldstein, M. J., … Levy, R. (2010). Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment. BLOOD, 116(21), 836–37.
  
• Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment Kohrt, H., & Advani, R. (2009). Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment. LEUKEMIA & LYMPHOMA, 50(11), 1773–84.
  
• Belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-Cell lymphoma: Results of a phase II study Advani, R., Hymes, K., Pohlman, B., Jacobsen, E., McDonnell, J., Belt, R., … Foss, F. (2007). Belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-Cell lymphoma: Results of a phase II study. BLOOD, 110(11), 1012A–1012A.
  
• LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study. Advani, R., Talreja, N., Tibshirani, R., Zhao, S., Alizadeh, A., Briones, J., … Natkunam, Y. (2008). LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy (RCHOP): A Multicenter Validation Study. BLOOD, 112(11), 1291–91.
  
• Characteristics and outcomes of extranodal NK/t-cell lymphoma (ENKL): A North American (NA) multi-institutional experience. Maeda, L. S., Geiger, J. L., Savage, K. J., Rose, J., Pinter-Brown, L. C., Lunning, M. A., … Advani, R. (2012). Characteristics and outcomes of extranodal NK/t-cell lymphoma (ENKL): A North American (NA) multi-institutional experience. JOURNAL OF CLINICAL ONCOLOGY, 30(15).
  
• A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Palanca-Wessels, M. C., Flinn, I. W., Sehn, L. H., Patel, M., Sangha, R., Czuczman, M. S., … Assouline, S. E. (2012). A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). BLOOD, 120(21).
  
• Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years Advani, R. H., Li, H., Hoppe, R. T., Bartlett, N. L., Bennett, J. M., Neuberg, D. S., … Horning, S. J. (2012). Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years. BLOOD, 120(21).
  
• A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Chin, D. L., Jacobs, C. D., & Sikic, B. I. (2005). A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. ANNALS OF ONCOLOGY, 16(12), 1968–73.
  
• Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical Trials Koontz, M. Z., Horning, S. J., Balise, R., Greenberg, P. L., Rosenberg, S. A., Hoppe, R. T., & Advani, R. H. (2013). Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma: The Stanford University Experience Over Three Generations of Clinical Trials. JOURNAL OF CLINICAL ONCOLOGY, 31(5), 592–98.
  
• Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial Advani, R. H., Hong, F., Horning, S. J., Kahl, B. S., Manola, J., Swinnen, L. J., … Ganjoo, K. (2012). Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial. LEUKEMIA & LYMPHOMA, 53(4), 718–20.
  
• Motexafin gadolinium (MGd) has clinical activity in relapsed/refractory low grade lymphomas (LG) and relapsed/refractory chronic lymphocytic leukemia (CLL). Kahl, B. S., Advani, R., Kay, N., Lossos, I. S., Evens, A., Gordon, L., … Phan, S. C. (2005). Motexafin gadolinium (MGd) has clinical activity in relapsed/refractory low grade lymphomas (LG) and relapsed/refractory chronic lymphocytic leukemia (CLL). BLOOD, 106(11), 269B–270B.
  
• Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, R., Talreja, N., … Levy, R. (2009). Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions. BLOOD, 114(22), 258–58.
  
• A prospective trial of involved field radiation (IFRT) plus chemotherapy vs extended field (EFRT) radiation for favorable Hodgkin's disease (HD): Long-term follow-up and implications for current combined modality therapy Horning, S. J., Hoppe, R. T., Advani, R. H., Breslin, S., McCormick, E., Allen, J., … Rosenberg, S. A. (2007). A prospective trial of involved field radiation (IFRT) plus chemotherapy vs extended field (EFRT) radiation for favorable Hodgkin's disease (HD): Long-term follow-up and implications for current combined modality therapy. Presented at the 7th International Symposium on Hodgkins Lymphoma, COLOGNE,GERMANY,GERMANY,GERMANY,GERMANY,GERMANY,GERMANY,GERMANY,GERMANY,GERMANY: FERRATA STORTI FOUNDATION.
  
• Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease Tseng, D., Rachakonda, L. P., Su, Z., Advani, R., Horning, S., Hoppe, R. T., … Tran, P. T. (2012). Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease. RADIATION ONCOLOGY, 7.
  
• Non-Hodgkin's Lymphomas Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., Bellam, N., … Zafar, N. (2011). Non-Hodgkin's Lymphomas. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(5), 484–560.
  
• Bexarotene is highly active in the treatment of subcutaneous Panniculitis-like T-cell lymphoma. Molina, A. M., Advani, R., Reddy, S., Hoppe, R., Friedberg, J. W., Sadan, S., … Horwitz, S. M. (2005). Bexarotene is highly active in the treatment of subcutaneous Panniculitis-like T-cell lymphoma. BLOOD, 106(11), 934A–934A.
  
• Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia Treon, S. P., Tripsas, C. K., Meid, K., Warren, D., Varma, G., Green, R., … Advani, R. H. (2015). Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia. NEW ENGLAND JOURNAL OF MEDICINE, 372(15), 1430–40.
  
• Improved prognosis after histologic transformation (HT) of follicular lymphoma (FL): The Stanford experience 1960-2003 Tan, D., Rosenberg, S. A., Lavori, P., Levy, R., Hoppe, R., Warnke, R., … Horning, S. J. (2008). Improved prognosis after histologic transformation (HT) of follicular lymphoma (FL): The Stanford experience 1960-2003. Presented at the 10th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND: OXFORD UNIV PRESS.
  
• Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. Hoppe, R. T., Advani, R. H., Bierman, P. J., Bloomfield, C. D., Buadi, F., Djulgegovic, B., … Zelenetz, A. D. (2006). Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network , 4(3), 210–230.
  
• Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. Bartlett, N. L., Chen, R., Fanale, M. A., Brice, P., Gopal, A., Smith, S. E., … Forero-Torres, A. (2014). Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. Journal of Hematology & Oncology, 7, 24-?
  
• Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin Horwitz, S. M., Advani, R. H., Bartlett, N. L., Jacobsen, E. D., Sharman, J. P., O'Connor, O. A., … Oki, Y. (2014). Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. BLOOD, 123(20), 3095–3100.
  
• Assessment of favorable (F) versus unfavorable (U) early stage Hodgkin's disease (HD); the Stanford V plus radiotherapy (RT) experience. Advani, R., Maeda, L., Hoppe, R. T., Breslin, S., Rosenberg, S. A., Baer, D., … Horning, S. J. (2005). Assessment of favorable (F) versus unfavorable (U) early stage Hodgkin's disease (HD); the Stanford V plus radiotherapy (RT) experience. BLOOD, 106(11), 548A–548A.
  
• Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine in refractory and advanced malignancies Galatin, P. S., Advani, R. H., Fisher, G. A., Francisco, B., Julian, T., Losa, R., … Sikic, B. I. (2011). Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine in refractory and advanced malignancies. INVESTIGATIONAL NEW DRUGS, 29(5), 971–77.
  
• Customized Targeted Therapy in Hodgkin Lymphoma: Hype or Hope? Diefenbach, C., & Advani, R. (2014). Customized Targeted Therapy in Hodgkin Lymphoma: Hype or Hope? HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 28(1), 105-?
  
• Anxiety and Health-Related Quality of Life Among Patients With Low-Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Results From ECOG Trial E4402 (RESORT) Wagner, L. I., Zhao, F., Hong, F., Williams, M. E., Gascoyne, R. D., Krauss, J. C., … Kahl, B. S. (2015). Anxiety and Health-Related Quality of Life Among Patients With Low-Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Results From ECOG Trial E4402 (RESORT). JOURNAL OF CLINICAL ONCOLOGY, 33(7).
  
• Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. Advani, R. H., Horning, S. J., Hoppe, R. T., Daadi, S., Allen, J., Natkunam, Y., & Bartlett, N. L. (2014). Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. Journal of Clinical Oncology , 32(9), 912–18.
  
• Incidence of secondary leukemia/myelodysplasia (AML/MDS) in Hodgkin's disease (HD) with three generations of therapy at Stanford University. Advani, R. H., Hoppe, R. T., Rosenberg, S. A., & Horning, S. J. (2006). Incidence of secondary leukemia/myelodysplasia (AML/MDS) in Hodgkin's disease (HD) with three generations of therapy at Stanford University. JOURNAL OF CLINICAL ONCOLOGY, 24(18), 426S–426S.
  
• Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Chang, J. E., Li, H., Smith, M. R., Gascoyne, R. D., Paietta, E. M., Yang, D. T., … Kahl, B. S. (2014). Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). Blood, 123(11), 1665–73.
  
• Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results Wang, M. L., Blum, K. A., Martin, P., Goy, A., Auer, R., Kahl, B. S., … Rule, S. (2015). Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. BLOOD, 126(6), 739–45.
  
• Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP Malumbres, R., Chen, J., Tibshirani, R., Johnson, N. A., Sehn, L. H., Natkunam, Y., … Lossos, I. S. (2008). Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. BLOOD, 111(12), 5509–14.
  
• ACR APPROPRIATENESS CRITERIA (R) Localized Nodal Indolent Lymphoma Hoppe, B. S., Hodgson, D. C., Advani, R., Dabaja, B. S., Flowers, C. R., Ha, C. S., … Constine, L. S. (2013). ACR APPROPRIATENESS CRITERIA (R) Localized Nodal Indolent Lymphoma. ONCOLOGY-NEW YORK, 27(8), 786–94.
  
• PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. Roemer, M. G. M., Advani, R. H., Ligon, A. H., Natkunam, Y., Redd, R. A., Homer, H., … Shipp, M. A. (2016). PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. Journal of Clinical Oncology , 34(23), 2690–97.
  
• Non-Hodgkin's Lymphomas, Version 4.2014. Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2014). Non-Hodgkin's Lymphomas, Version 4.2014. Journal of the National Comprehensive Cancer Network , 12(9), 1282–1303.
  
• Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines Tan, D., Tan, S. Y., Lim, S. T., Kim, S. J., Kim, W.-S., Advani, R., & Kwong, Y.-L. (2013). Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines. LANCET ONCOLOGY, 14(12), E548–E561.
  
• Validation of the Elderly IPI (E-IPI) for Patients with Diffuse Large B Cell Lymphoma Using An Independent Data Set From the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) Advani, R. H., Hong, F., Li, H., Kahl, B. S., Pfreundschuh, M., & Ziepert, M. (2011). Validation of the Elderly IPI (E-IPI) for Patients with Diffuse Large B Cell Lymphoma Using An Independent Data Set From the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). BLOOD, 118(21), 681–81.
  
• In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., Advani, R. H., … Levy, R. (2010). In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study. JOURNAL OF CLINICAL ONCOLOGY, 28(28), 4324–32.
  
• Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial Tan, K. L., Scott, D. W., Hong, F., Kahl, B. S., Fisher, R. I., Bartlett, N. L., … Gascoyne, R. D. (2012). Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. BLOOD, 120(16), 3280–87.
  
• Current concepts and controversies in the management of early stage Hodgkin lymphoma Maeda, L. S., Lee, M., & Advani, R. H. (2011). Current concepts and controversies in the management of early stage Hodgkin lymphoma. LEUKEMIA & LYMPHOMA, 52(6), 962–71.
  
• Classical Hodgkin Lymphoma with Reduced ß2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. Roemer, M. G. M., Advani, R. H., Redd, R. A., Pinkus, G. S., Natkunam, Y., Ligon, A. H., … Rodig, S. J. (2016). Classical Hodgkin Lymphoma with Reduced ß2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. Cancer Immunology Research, 4(11), 910–16.
  
• NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Bello, C. M., Bierman, P. J., … Yahalom, J. (2011). NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(9), 1020–58.
  
• The landscape of new drugs in lymphoma Younes, A., Ansell, S., Fowler, N., Wilson, W., de Vos, S., Seymour, J., … Vose, J. (2017). The landscape of new drugs in lymphoma. NATURE REVIEWS CLINICAL ONCOLOGY, 14(6), 335–46.
  
• Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30(+) Peripheral T-Cell Lymphomas: Results of a Phase I Study Fanale, M. A., Horwitz, S. M., Forero-Torres, A., Bartlett, N. L., Advani, R. H., Pro, B., … Shustov, A. R. (2014). Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30(+) Peripheral T-Cell Lymphomas: Results of a Phase I Study. JOURNAL OF CLINICAL ONCOLOGY, 32(28), 3137-?
  
• Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., … Horwitz, S. M. (2015). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of Clinical Oncology , 33(32), 3750–58.
  
• Role or FDG-PET/CT Surveillance for Patients with Classical Hodgkin's Disease in First Complete Response: The Stanford University Experience. Maeda, L. S., Horning, S. J., Iagaru, A. H., Lin, F. I., Hoppe, R. T., Rosenberg, S. A., & Advani, R. H. (2009). Role or FDG-PET/CT Surveillance for Patients with Classical Hodgkin's Disease in First Complete Response: The Stanford University Experience. BLOOD, 114(22), 626–26.
  
• Multicenter Phase I Trial of Intraventricular Immuno-Chemotherapy in Recurrent CNS Lymphoma Rubenstein, J. L., Chen, L., Advani, R., Drappatz, J., Gerstner, E., Batchelor, T., … Damon, L. E. (2011). Multicenter Phase I Trial of Intraventricular Immuno-Chemotherapy in Recurrent CNS Lymphoma. BLOOD, 118(21), 438–39.
  
• The Clonal Architecture of CXCR4mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability Xu, L., Hunter, Z., Tsakmaklis, N., Cao, Y., Yang, G., Chen, J., … Treon, S. P. (2015). The Clonal Architecture of CXCR4mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability. BLOOD, 126(23).
  
• Non-Hodgkin's Lymphomas, Version 2.2014. Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2014). Non-Hodgkin's Lymphomas, Version 2.2014. Journal of the National Comprehensive Cancer Network , 12(6), 916–946.
  
• Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. Zelenetz, A. D., Advani, R. H., Buadi, F., Cabanillas, F., Caligiuri, M. A., Czuczman, M. S., … Yahalom, J. (2006). Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network , 4(3), 258–310.
  
• Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies Marostica, E., Sukbuntherng, J., Loury, D., de Jong, J., de Trixhe, X. W., Vermeulen, A., … Poggesi, I. (2015). Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 75(1), 111–21.
  
• Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., … Shustov, A. (2012). Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. JOURNAL OF CLINICAL ONCOLOGY, 30(18), 2190–96.
  
• Magnetic Resonance Imaging of Tumor Associated Macrophages: Clinical Translation. Aghighi, M., Theruvath, A. J., Pareek, A., Pisani, L., Alford, R., Muehe, A. M., … Daldrup-Link, H. E. (2018). Magnetic Resonance Imaging of Tumor Associated Macrophages: Clinical Translation. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
  
• The 2016 revision of the World Health Organization classification of lymphoid neoplasms Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., … Jaffe, E. S. (2016). The 2016 revision of the World Health Organization classification of lymphoid neoplasms. BLOOD, 127(20), 2375–90.
  
• Classical Hodgkin Lymphoma in First Complete Remission: Is There a Role for F-18 FDG PET/CT Surveillance? Lagaru, A., Maeda, L. S., Lin, F. I., Hoppe, R. T., Rosenberg, S. A., Gambhir, S. S., & Advani, R. H. (2010). Classical Hodgkin Lymphoma in First Complete Remission: Is There a Role for F-18 FDG PET/CT Surveillance? Presented at the 23rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), VIENNA,AUSTRIA,AUSTRIA,AUSTRIA,AUSTRIA,AUSTRIA,AUSTRIA,AUSTRIA: SPRINGER.
  
• Speeding up PET/MR for cancer staging of children and young adults. Aghighi, M., Pisani, L. J., Sun, Z., Klenk, C., Madnawat, H., Fineman, S. L., … Daldrup-Link, H. E. (2016). Speeding up PET/MR for cancer staging of children and young adults. European Radiology, -?
  
• Non-Hodgkin's Lymphomas, Version 3.2016 Featured Updates to the NCCN Guidelines Horwitz, S. M., Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., … Porcu, P. (2016). Non-Hodgkin's Lymphomas, Version 3.2016 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(9), 1067–79.
  
• Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+Lymphomas Illidge, T., Bouabdallah, R., Chen, R. W., Gopal, A. K., Moskowitz, C. H., Ramchandren, R., … Advani, R. H. (2011). Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+Lymphomas. BLOOD, 118(21), 1335–36.
  
• Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. Tao, L., Clarke, C. A., Rosenberg, A. S., Advani, R. H., Jonas, B. A., Flowers, C. R., & Keegan, T. H. M. (2017). Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. British Journal of Haematology.
  
• CD81 Protein Is Expressed in Normal Germinal Center B-Cells and in Subtypes of Human Non-Hodgkin Lymphomas Luo, R. F., Zhao, S., Tibshirani, R., Lossos, I. S., Advani, R., Gratzinger, D., … Natkunam, Y. (2009). CD81 Protein Is Expressed in Normal Germinal Center B-Cells and in Subtypes of Human Non-Hodgkin Lymphomas. LABORATORY INVESTIGATION, 89, 275A.
  
• Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides or Sezary Syndrome: Final Results Show Significant Clinical Activity and Suggest Correlation with CD30 Expression Kim, Y. H., Tavallaee, M., Rozati, S., Sundram, U., Salva, K., Wood, G. S., … Horwitz, S. M. (2014). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides or Sezary Syndrome: Final Results Show Significant Clinical Activity and Suggest Correlation with CD30 Expression. BLOOD, 124(21).
  
• ACR Appropriateness Criteria (R) on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II Das, P., Ng, A., Constine, L. S., Advani, R., Flowers, C., Friedberg, J., … Yunes, M. J. (2011). ACR Appropriateness Criteria (R) on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II. JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY, 8(5), 302–8.
  
• Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma Scherer, F., Kurtz, D. M., Newman, A. M., Esfahani, M. S., Craig, A., Stehr, H., … Alizadeh, A. A. (2016). Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma. BLOOD, 128(22).
  
• Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring Minamimoto, R., Fayad, L., Advani, R., Vose, J., Macapinlac, H., Meza, J., … Quon, A. (2016). Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring. RADIOLOGY, 280(1), 220–29.
  
• in Situ Vaccination for Patients with Previously Untreated Follicular Lymphoma: Analysis of Immune Responses Czerwinski, D. K., Brody, J., Kohrt, H. E., Hoppe, R. T., Advani, R. H., & Levy, R. (2012). in Situ Vaccination for Patients with Previously Untreated Follicular Lymphoma: Analysis of Immune Responses. BLOOD, 120(21).
  
• NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017. Wierda, W. G., Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2017). NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017. Journal of the National Comprehensive Cancer Network , 15(3), 293–311.
  
• Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab Morales, A. V., Advani, R., Horwitz, S. M., Riaz, N., Reddy, S., Hoppe, R. T., & Kim, Y. H. (2008). Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 59(6), 953–57.
  
• The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405-A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL. Kahl, B. S., Li, H., Smith, M. R., Gascoyne, R. D., Paietta, E., Advani, R., & Horning, S. J. (2009). The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405-A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL. BLOOD, 114(22), 663–63.
  
• Cancer Vaccines and T Cell Therapy Rezvani, K., Brody, J. D., Kohrt, H. E., Logan, A. C., Advani, R., Czerwinski, D. K., … Barrett, J. (2013). Cancer Vaccines and T Cell Therapy. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(1), S97–S101.
  
• A Clinicopathologic Review of 215 Cases of Angioimmunoblastic T-Cell Lymphoma with Emphasis on the Significance of B-Cell Proliferations Ohgami, R. S., Chen, J. S., Advani, R., Natkunam, Y., & Warnke, R. A. (2014). A Clinicopathologic Review of 215 Cases of Angioimmunoblastic T-Cell Lymphoma with Emphasis on the Significance of B-Cell Proliferations. MODERN PATHOLOGY, 27, 366A–367A.
  
• Exploratory study of brentuximab vedotin (SGN-35), a novel monoclonal antibody-drug-conjugate against CD30, in mycosis fungoides (MF) and Sezary syndrome (SS) demonstrates clinical responses regardless of CD30 expression levels Bashey, S., Krathen, M., Sutherland, K., Sundram, U., Lingala, B., Horwitz, S., … Kim, Y. (2012). Exploratory study of brentuximab vedotin (SGN-35), a novel monoclonal antibody-drug-conjugate against CD30, in mycosis fungoides (MF) and Sezary syndrome (SS) demonstrates clinical responses regardless of CD30 expression levels. Presented at the 75th Annual Meeting of the Society-for-Investigative-Dermatology, RALEIGH,NC,NC,NC,NC,NC,NC,NC: NATURE PUBLISHING GROUP.
  
• Mature Results From ECOG Study E1405-A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma Kahl, B. S., Li, H., Smith, M. R., Gascoyne, R. D., Yang, D. T., Paietta, E., … Horning, S. J. (2012). Mature Results From ECOG Study E1405-A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma. BLOOD, 120(21).
  
• Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD plus Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496 Advani, R., Hong, F., Gordon, L. I., Gascoyne, R. D., Wagner, H., Hoppe, R. T., … Horning, S. J. (2011). Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD plus Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496. BLOOD, 118(21), 696–97.
  
• Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2015). Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. Journal of the National Comprehensive Cancer Network , 13(3), 326–362.
  
• A phase 1 trial of weekly SNS-595 in patients (PTS) with refractory cancer Ebbinghaus, S., Gordon, M., Advani, R., Hurwitz, H., Mendelson, D., Wakelee, H., … Adelman, D. (2006). A phase 1 trial of weekly SNS-595 in patients (PTS) with refractory cancer. CANCER RESEARCH, 66(8).
  
• Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression Krathen, M., Sundram, U., Bashey, S., Sutherland, K., Salva, K., Wood, G. S., … Kim, Y. H. (2012). Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression. BLOOD, 120(21).
  
• The effect of oral valspodar (psc 833), a modulator of multidrug resistance, on the pharmacokinetics of liposomal doxorubicin. Lum, B. L., Chin, D. L., Cho, C. D., Advani, R., Fisher, G. A., Halsey, J., & Sikic, B. I. (2002). The effect of oral valspodar (psc 833), a modulator of multidrug resistance, on the pharmacokinetics of liposomal doxorubicin. CLINICAL PHARMACOLOGY & THERAPEUTICS, 71(2), P48–P48.
  
• Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Ganjoo, K., Hong, F., Horning, S. J., Gascoyne, R. D., Natkunam, Y., Swinnen, L. J., … Advani, R. H. (2014). Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leukemia & Lymphoma, 55(4), 768–72.
  
• Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: Randomized phase III trial (E2995). Greenberg, P., Advani, R., Tallman, M., Letendre, L., Saba, H., Dugan, K., … Rowe, J. M. (1999). Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: Randomized phase III trial (E2995). BLOOD, 94(10), 383A–383A.
  
• Prognostic Factors, Treatment, and Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab (R) Era Hiniker, S. M., Pollom, E. L., Khodadoust, M. S., Kozak, M. M., Advani, R. H., & Hoppe, R. T. (2014). Prognostic Factors, Treatment, and Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab (R) Era. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90, S677–S678.
  
• A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. Fishe, G. A., Kuo, T., Cho, C. D., Halsey, J., Jambalos, C. N., Schwartz, E. J., … Wakelee, H. A. (2004). A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 22(14), 248S–248S.
  
• Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Bello, C. M., … Sundar, H. (2017). Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network , 15(5), 608–38.
  
• Management of advanced stage Hodgkin lymphoma. Advani, R., Ai, W. Z., & Horning, S. J. (2006). Management of advanced stage Hodgkin lymphoma. Journal of the National Comprehensive Cancer Network , 4(3), 241–47.
  
• Clinical Impact of the 2016 Update to the WHO Lymphoma Classification. Lynch, R. C., Gratzinger, D., & Advani, R. H. (2017). Clinical Impact of the 2016 Update to the WHO Lymphoma Classification. Current Treatment Options in Oncology, 18(7), 45.
  
• Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging. Iberri, D. J., Hoppe, R. T., & Advani, R. H. (2015). Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging. Current Treatment Options in Oncology, 16(9), 45-?
  
• Single-agent ibrutinib for the treatment of mantle cell lymphoma (MCL): evaluating the link between durable response and quality of life (QoL) in the SPARK study Rule, S., Goy, A., Martin, P., Ramchandren, R., Alexeeva, J., Popat, R., … Wang, M. (2015). Single-agent ibrutinib for the treatment of mantle cell lymphoma (MCL): evaluating the link between durable response and quality of life (QoL) in the SPARK study. BRITISH JOURNAL OF HAEMATOLOGY, 169, 59.
  
• Phase II study of bortezomib in Waldenstrom's Macroglobulinemia: Results of WMCTG trial 03-248. Treon, S., Hunter, Z. R., Matous, J., Badros, A., Joyce, R. M., Mannion, B., … Patterson, C. J. (2005). Phase II study of bortezomib in Waldenstrom's Macroglobulinemia: Results of WMCTG trial 03-248. BLOOD, 106(11), 147A–147A.
  
• A Clinicopathologic Review of 215 Cases of Angioimmunoblastic T-Cell Lymphoma with Emphasis on the Significance of B-Cell Proliferations Ohgami, R. S., Chen, J. S., Advani, R., Natkunam, Y., & Warnke, R. A. (2014). A Clinicopathologic Review of 215 Cases of Angioimmunoblastic T-Cell Lymphoma with Emphasis on the Significance of B-Cell Proliferations. LABORATORY INVESTIGATION, 94, 366A–367A.
  
• Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas. Aalipour, A., & Advani, R. H. (2013). Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas. British Journal of Haematology, 163(4), 436–43.
  
• THE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, IBRUTINIB (PCI-32765), HAS PREFERENTIAL ACTIVITY IN THE ACTIVATED B CELL-LIKE (ABC) SUBTYPE OF RELAPSED/REFRACTORY (R/R) DLBCL: INTERIM PHASE 2 RESULTS deVos, S., Wilson, W., Gerecitano, J., Goy, A., Kenkre, V., Barr, P., … Staudt, L. (2013). THE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, IBRUTINIB (PCI-32765), HAS PREFERENTIAL ACTIVITY IN THE ACTIVATED B CELL-LIKE (ABC) SUBTYPE OF RELAPSED/REFRACTORY (R/R) DLBCL: INTERIM PHASE 2 RESULTS. HAEMATOLOGICA, 98, 490.
  
• Survival in follicular lymphoma: The Stanford experience, 1960-2003. Tan, D., Rosenberg, S. A., Levy, R., Lavori, P., Tibshirani, R., Hoppe, R. T., … Horning, S. J. (2007). Survival in follicular lymphoma: The Stanford experience, 1960-2003. BLOOD, 110(11), 1005A–1005A.
  
• Non-Hodgkin's Lymphomas Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Byrd, J. C., Czuczman, M. S., … Yunus, F. (2010). Non-Hodgkin's Lymphomas. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 8(3), 288–334.
  
• Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage Hodgkin lymphoma (HL): Analysis from the phase III randomized US Intergroup Trial E2496 Evens, A. M., Hong, F., Gordon, L. I., Fisher, R. I., Bartlett, N., Connors, J. M., … Horning, S. J. (2011). Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage Hodgkin lymphoma (HL): Analysis from the phase III randomized US Intergroup Trial E2496. JOURNAL OF CLINICAL ONCOLOGY, 29(15).
  
• Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules Advani, R. H., Hurwitz, H. I., Gordon, M. S., Ebbinghaus, S. W., Mendelson, D. S., Wakelee, H. A., … Adelman, D. C. (2010). Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules. CLINICAL CANCER RESEARCH, 16(7), 2167–75.
  
• Non-Hodgkin's lymphomas. Zelenetz, A. D., Advani, R. H., Byrd, J. C., Czuczman, M. S., Damon, L. E., Duvic, M., … Yunus, F. (2008). Non-Hodgkin's lymphomas. Journal of the National Comprehensive Cancer Network , 6(4), 356–421.
  
• Bulky Mediastinal Classical Hodgkin Lymphoma in Young Women Percival, M.-E. M., Hoppe, R. T., & Advani, R. H. (2014). Bulky Mediastinal Classical Hodgkin Lymphoma in Young Women. ONCOLOGY-NEW YORK, 28(3), 253-+.
  
• ACR Appropriateness Criteria: Localized nodal indolent lymphoma. Hoppe, B. S., Hodgson, D. C., Advani, R., Dabaja, B. S., Flowers, C. R., Ha, C. S., … Constine, L. S. (2013). ACR Appropriateness Criteria: Localized nodal indolent lymphoma. Oncology (Williston Park, N.Y.), 27(8), 786–794.
  
• Stage I/II Hodgkin's disease (HD) with bulky mediastinal disease or other risk factors (RF) the Stanford V experience Advani, R. H., Hoppe, R. T., Rosenberg, S. A., & Horning, S. J. (2007). Stage I/II Hodgkin's disease (HD) with bulky mediastinal disease or other risk factors (RF) the Stanford V experience. Presented at the 7th International Symposium on Hodgkins Lymphoma, COLOGNE,GERMANY,GERMANY,GERMANY,GERMANY,GERMANY,GERMANY,GERMANY: FERRATA STORTI FOUNDATION.
  
• Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus (EBV) antigens in patients with EBV-negative Hodgkin's disease Kohrt, H. E., Advani, R., Hoppe, R., Rosenberg, S., Horning, S., & Lee, P. P. (2009). Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus (EBV) antigens in patients with EBV-negative Hodgkin's disease. JOURNAL OF CLINICAL ONCOLOGY, 27(15).
  
• ACR appropriateness Criteria® pediatric Hodgkin lymphoma. Terezakis, S. A., Metzger, M. L., Hodgson, D. C., Schwartz, C. L., Advani, R., Flowers, C. R., … Constine, L. S. (2014). ACR appropriateness Criteria® pediatric Hodgkin lymphoma. Pediatric Blood & Cancer, 61(7), 1305–12.
  
• First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Byrd, J. C., Smith, S., Wagner-Johnston, N., Sharman, J., Chen, A. I., Advani, R., … Flinn, I. W. (2018). First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget, 9(16), 13023–35.
  
• Evaluation of Radiation Therapy for NK-T-cell Lymphoma of the Head and Neck Chan, C., Zeidan, Y. H., Advani, R., Le, Q., & Hoppe, R. T. (2012). Evaluation of Radiation Therapy for NK-T-cell Lymphoma of the Head and Neck. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3), S618–S619.
  
• Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study Palanca-Wessels, M. C. A., Czuczman, M., Salles, G., Assouline, S., Sehn, L. H., Flinn, I., … Morschhauser, F. (2015). Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. LANCET ONCOLOGY, 16(6), 704–15.
  
• NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. Horwitz, S. M., Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., … Porcu, P. (2016). NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. Journal of the National Comprehensive Cancer Network , 14(9), 1067–79.
  
• Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., … Alizadeh, A. A. (2018). Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2018785246.
  
• Brentuximab vedotin plus chemotherapy for stage III/IV classical Hodgkin lymphoma: 4-year update of the ECHELON-1 study Radford, J., Bartlett, N., Straus, D., Dlugosz-Danecka, M., Alekseev, S., Illes, A., … Picardi, M. (2020). Brentuximab vedotin plus chemotherapy for stage III/IV classical Hodgkin lymphoma: 4-year update of the ECHELON-1 study. BRITISH JOURNAL OF HAEMATOLOGY, 189, 101–2.
  
• Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Advani, R. H., Lebovic, D., Chen, A., Brunvand, M., Goy, A., Chang, J. E., … Cheson, B. D. (2017). Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 23(5), 1167–76.
  
• Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory hodgkin lymphoma: twenty years experience at a single institution. Garfin, P. M., Link, M. P., Donaldson, S. S., Advani, R. H., Luna-Fineman, S., Kharbanda, S., … Agarwal-Hashmi, R. (2015). Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory hodgkin lymphoma: twenty years experience at a single institution. Biology of Blood and Marrow Transplantation , 21(2), 326–34.
  
• Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. Fanale, M. A., Horwitz, S. M., Forero-Torres, A., Bartlett, N. L., Advani, R. H., Pro, B., … Shustov, A. R. (2014). Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. Journal of Clinical Oncology , 32(28), 3137–43.
  
• Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. Hsi, E. D., Horwitz, S. M., Carson, K. R., Pinter-Brown, L. C., Rosen, S. T., Pro, B., … Foss, F. M. (2017). Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. Clinical Lymphoma, Myeloma & Leukemia.
  
• Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL) Scherer, F., Kurtz, D. M., Green, M. R., Newman, A. M., Klass, D. M., Zhou, L., … Alizadeh, A. A. (2015). Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL). JOURNAL OF CLINICAL ONCOLOGY, 33(15).
  
• Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing Schroers-Martin, J. G., Garofalo, A., Soo, J., Jin, M. C., Kurtz, D. M., Buedts, L., … Alizadeh, A. A. (2018). Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing. BLOOD, 132.
  
• Long-term safety and efficacy of single-agent lbrutinib in patients with relapsed or refractory mantle cell lymphoma: Updated results of an international, multicenter, open-label phase 2 study Dreyling, M., Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., … Blum, K. A. (2015). Long-term safety and efficacy of single-agent lbrutinib in patients with relapsed or refractory mantle cell lymphoma: Updated results of an international, multicenter, open-label phase 2 study. Oncology Research and Treatment, 38, 18–19.
  
• Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes Bannerji, R., Arnason, J. E., Advani, R., Brown, J. R., Allan, J. N., Ansell, S. M., … Topp, M. S. (2018). Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes. BLOOD, 132.
  
• A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I) Diefenbach, C., Hong, F., Ambinder, R. F., Cohen, J. B., Robertson, M., David, K. A., … Ansell, S. M. (2018). A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I). BLOOD, 132.
  
• Prognostic significance of CD15 expression in classical Hodgkin lymphoma (cHL): The Stanford University experience Maeda, L. S., Hoppe, R. T., Warnke, R. A., Natkunam, Y., Rosenberg, S. A., Homing, S. J., & Advani, R. (2010). Prognostic significance of CD15 expression in classical Hodgkin lymphoma (cHL): The Stanford University experience. JOURNAL OF CLINICAL ONCOLOGY, 28(15).
  
• Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Bello, C. M., … Sundar, H. (2012). Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(5), 589–97.
  
• NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. Zelenetz, A. D., Abramson, J. S., Advani, R. H., Andreadis, C. B., Byrd, J. C., Czuczman, M. S., … Yunus, F. (2010). NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. Journal of the National Comprehensive Cancer Network , 8(3), 288–334.
  
• PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome Roemer, M. G. M., Advani, R. H., Ligon, A. H., Natkunam, Y., Redd, R. A., Homer, H., … Shipp, M. A. (2015). PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. BLOOD, 126(23).
  
• Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., … Blum, K. A. (2013). Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. NEW ENGLAND JOURNAL OF MEDICINE, 369(6), 507–16.
  
• Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Pfeifer, M., Zheng, B., Erdmann, T., Koeppen, H., McCord, R., Grau, M., … Lenz, G. (2015). Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia, 29(7), 1578–86.
  
• Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404) Swinnen, L. J., Li, H., Quon, A., Gascoyne, R., Hong, F., Ranheim, E. A., … Advani, R. H. (2015). Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). BRITISH JOURNAL OF HAEMATOLOGY, 170(1), 56–65.
  
• Management of nodular lymphocyte predominant Hodgkin lymphoma Advani, R. H., & Hoppe, R. T. (2015). Management of nodular lymphocyte predominant Hodgkin lymphoma. HEMATOLOGICAL ONCOLOGY, 33, 90–95.
  
• The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496 Evens, A. M., Hong, F., Gordon, L. I., Fisher, R. I., Bartlett, N. L., Connors, J. M., … Horning, S. J. (2013). The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. BRITISH JOURNAL OF HAEMATOLOGY, 161(1), 76–86.
  
• Prognostic role of baseline 18F-FDG PET/CT in DLBCL patients Baratto, L., Wu, F., Minamimoto, R., Sabile, J., Advani, R., & Mittra, E. (2016). Prognostic role of baseline 18F-FDG PET/CT in DLBCL patients. JOURNAL OF NUCLEAR MEDICINE, 57.
  
• Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG) Dabaja, B. S., Zelenetz, A. D., Ng, A. K., Tsang, R. W., Qi, S., Allen, P. K., … Yahalom, J. (2017). Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG). ANNALS OF ONCOLOGY, 28(9), 2185–90.
  
• A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402 Witzig, T. E., Hong, F., Micallef, I. N., Gascoyne, R. D., Dogan, A., Wagner, H., … Horning, S. J. (2015). A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402. BRITISH JOURNAL OF HAEMATOLOGY, 170(5), 679–86.
  
• Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma Herrera, A. F., Moskowitz, A. J., Bartlett, N. L., Vose, J. M., Ramchandren, R., Feldman, T. A., … Advani, R. H. (2018). Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. BLOOD, 131(11), 1183–94.
  
• SNS-595 demonstrates clinical activity and dose-proportional pharmacokinetics (PK) in two phase I clinical studies. Hurwitz, H., Gordon, M., Advani, R., Ebbinghaus, S., Mendelson, D., Wakelee, H., … Adelman, D. (2006). SNS-595 demonstrates clinical activity and dose-proportional pharmacokinetics (PK) in two phase I clinical studies. JOURNAL OF CLINICAL ONCOLOGY, 24(18), 136S.
  
• Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y-90-Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499 Smith, M. R., Li, H., Hong, F., Gordon, L. I., Gascoyne, R. D., Paietta, E., … Kahl, B. S. (2015). Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y-90-Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499. BLOOD, 126(23).
  
• Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma Wilson, W. H., Young, R. M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., … Staudt, L. M. (2015). Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. NATURE MEDICINE, 21(8), 922–26.
  
• Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Bartlett, N. L., Smith, M. R., Siddiqi, T., Advani, R. H., O'Connor, O. A., Sharman, J. P., … Jacobsen, E. D. (2016). Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Leukemia & Lymphoma, 1–10.
  
• Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study Advani, R., Sharman, J. P., Smith, S. M., Pollyea, D. A., Boyd, T. E., Grant, B. W., … Fowler, N. H. (2010). Effect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study. JOURNAL OF CLINICAL ONCOLOGY, 28(15).
  
• Advances in the Management of Primary Mediastinal Large B-Cell Lymphoma Advani, R. H. (2018). Advances in the Management of Primary Mediastinal Large B-Cell Lymphoma. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 16(1), 33–34.
  
• PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA Witzig, T., Sokol, L., Jacobsen, E., Advani, R., Mondejar, R., Piris, M., … Gualberto, A. (2017). PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA. HAEMATOLOGICA, 102, 222.
  
• Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial Kanakry, J. A., Hong, F., Martinez-Maza, O., Horning, S. J., Gordon, L. I., Gascoyne, R. D., … Ambinder, R. F. (2016). Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial. BLOOD, 128(22).
  
• Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma in the Modern Era King, M. T., Donaldson, S. S., Link, M. P., Natkunam, Y., Advani, R. H., & Hoppe, R. T. (2015). Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma in the Modern Era. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 92(1), 67–75.
  
• The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group Constine, L. S., Yahalom, J., Ng, A. K., Hodgson, D. C., Wirth, A., Milgrom, S. A., … Hoppe, R. T. (2018). The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 100(5), 1100–1118.
  
• Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90-Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499 Smith, M. R., Li, H., Gordon, L., Gascoyne, R. D., Paietta, E., Forero-Torres, A., … Horning, S. J. (2012). Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90-Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. JOURNAL OF CLINICAL ONCOLOGY, 30(25), 3119–26.
  
• Clinical and Pathological Features of Non-Hodgkin Lymphomas Harboring Concurrent t(14;18) and 8q24 Anomalies Alizadeh, A. A., Anderson, M., Kohrt, H. E., Shyam, R. M., Bangs, C. D., Cherry, A. M., … Levy, R. (2010). Clinical and Pathological Features of Non-Hodgkin Lymphomas Harboring Concurrent t(14;18) and 8q24 Anomalies. BLOOD, 116(21), 1291–92.
  
• Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. Evens, A. M., Kanakry, J. A., Sehn, L. H., Kritharis, A., Feldman, T., Kroll, A., … Blum, K. A. (2015). Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort. American Journal of Hematology, 90(9), 778–83.
  
• A PHASE 2B TRIAL COMPARING DACETUZUMAB plus R-ICE VS PLACEBO plus R-ICE IN PATIENTS WITH RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA Fayad, L., Ansell, S. M., Advani, R., Coiffier, B., Bartlett, N. L., Stuart, R., … Drachman, J. G. (2011). A PHASE 2B TRIAL COMPARING DACETUZUMAB plus R-ICE VS PLACEBO plus R-ICE IN PATIENTS WITH RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA. ANNALS OF ONCOLOGY, 22, 132.
  
• Brentuximab Vedotin in Transplant-Naive Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies Forero-Torres, A., Fanale, M., Advani, R., Bartlett, N. L., Rosenblatt, J. D., Kennedy, D. A., & Younes, A. (2012). Brentuximab Vedotin in Transplant-Naive Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies. ONCOLOGIST, 17(8), 1073–80.
  
• Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Horwitz, S., O'Connor, O. A., Pro, B., Illidge, T., Fanale, M., Advani, R., … Trumper, L. (2018). Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet (London, England).
  
• A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era Hosein, P. J., Maragulia, J. C., Salzberg, M. P., Press, O. W., Habermann, T. M., Vose, J. M., … Lossos, I. S. (2014). A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. BRITISH JOURNAL OF HAEMATOLOGY, 165(3), 358–63.
  
• Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia Treon, S. P., Tsakmaklis, N., Meid, K., Yang, G., Chen, J. G., Liu, X., … Hunter, Z. (2016). Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia. BLOOD, 128(22).
  
• Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. Castillo, J. J., Palomba, M. L., Advani, R., & Treon, S. P. (2016). Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. Therapeutic Advances in Hematology, 7(4), 179–86.
  
• Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations Jan, M., Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Liu, C. L., … Alizadeh, A. A. (2016). Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations. BLOOD, 128(22).
  
• TWO DOSES OF POLATUZUMAB VEDOTIN (POV, ANTI-CD79B ANTI-BODY-DRUG CONJUGATE) PLUS RITUXIMAB (R) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): DURABLE RESPONSES AT LOWER DOSE LEVEL Sharman, J., Flinn, I., Advani, R., Diefenbach, C., Kolibaba, K., Press, O., … Morschhauser, F. (2015). TWO DOSES OF POLATUZUMAB VEDOTIN (POV, ANTI-CD79B ANTI-BODY-DRUG CONJUGATE) PLUS RITUXIMAB (R) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): DURABLE RESPONSES AT LOWER DOSE LEVEL. HAEMATOLOGICA, 100, 272.
  
• Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies: Phase 1 Results. Horwitz, S. M., Vose, J. M., Advani, R., Sankhala, K., Padmanabhan, S., Hamlin, P. A., … O'Connor, O. A. (2009). Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies: Phase 1 Results. BLOOD, 114(22), 667–68.
  
• Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI) Advani, R. H., Chen, H., Habermann, T. M., Morrison, V. A., Weller, E. A., Fisher, R. I., … Horning, S. J. (2010). Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). BRITISH JOURNAL OF HAEMATOLOGY, 151(2), 143–51.
  
• Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. Evens, A. M., Advani, R., Press, O. W., Lossos, I. S., Vose, J. M., Hernandez-Ilizaliturri, F. J., … Bartlett, N. L. (2013). Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. Journal of Clinical Oncology , 31(32), 4132–4139.
  
• Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation Gopal, A. K., Ramchandren, R., O'Connor, O. A., Berryman, R. B., Advani, R. H., Chen, R., … Zain, J. (2012). Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. BLOOD, 120(3), 560–68.
  
• Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma Scott, D. W., Chan, F. C., Hong, F., Rogic, S., Tan, K. L., Meissner, B., … Gascoyne, R. D. (2013). Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 31(6), 692–700.
  
• Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma Dunleavy, K., Pittaluga, S., Maeda, L. S., Advani, R., Chen, C. C., Hessler, J., … Wilson, W. H. (2013). Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma. NEW ENGLAND JOURNAL OF MEDICINE, 368(15), 1408–16.
  
• CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma Burington, B., Yue, P., Shi, X., Advani, R., Lau, J. T., Tan, J., … Dornan, D. (2011). CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma. SCIENCE TRANSLATIONAL MEDICINE, 3(74).
  
• Marked improvement in staging accuracy in mycosis fungoides/Sezary syndrome using integrated positron emission tomography and computed tomography (PET/CT) Tsai, E. Y., Taur, A., Espinosa, L., Quon, A., Dick, S. E., Chow, S., … Kim, Y. H. (2004). Marked improvement in staging accuracy in mycosis fungoides/Sezary syndrome using integrated positron emission tomography and computed tomography (PET/CT). BLOOD, 104(11), 854A–855A.
  
• Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Leblond, V., Kastritis, E., Advani, R., Ansell, S. M., Buske, C., Castillo, J. J., … Dimopoulos, M. A. (2016). Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood, 128(10), 1321–28.
  
• Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) Advani, R., Saba, H., Rowe, J. M., Tallman, M., Wiernik, P., Ramek, J., … Greenberg, P. (1996). Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC). BLOOD, 88(10), 847.
  
• Novel Approaches in Waldenstrom Macroglobulinemia Spinner, M. A., Varma, G., & Advani, R. H. (2018). Novel Approaches in Waldenstrom Macroglobulinemia. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 32(5), 875-+.
  
• A PHASE I TRIAL OF BTK INHIBITOR PCI-32765 IN PATIENTS WITH RELAPSED NON-HODGKIN'S LYMPHOMA: EVIDENCE OF ANTITUMOR ACTIVITY Fowler, N., Sharman, J., Smith, S., Pollyea, D., Boyd, T., Grant, B., … Advani, R. (2010). A PHASE I TRIAL OF BTK INHIBITOR PCI-32765 IN PATIENTS WITH RELAPSED NON-HODGKIN'S LYMPHOMA: EVIDENCE OF ANTITUMOR ACTIVITY. HAEMATOLOGICA, 95, 371.
  
• A phase I trial of sns-314, a novel and selective pan-aurora kinase inhibitor, in advanced solid tumor patients Robert, F., Verschraegen, C., Hurwitz, H., Uronis, H., Advani, R., Chen, A., … Michelson, G. (2009). A phase I trial of sns-314, a novel and selective pan-aurora kinase inhibitor, in advanced solid tumor patients. JOURNAL OF CLINICAL ONCOLOGY, 27(15).
  
• Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E) Diefenbach, C. S., Hong, F., David, K. A., Cohen, J., Robertson, M., Advani, R., … Ansell, S. (2016). Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E). BLOOD, 128(22).
  
• A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Relapsed/Refactory B-Lineage Non-Hodgkin Lymphoma Moskowitz, C. H., Fanale, M. A., Shah, B. D., Advani, R. H., Chen, R., Kim, S., … Forero-Torres, A. (2015). A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Relapsed/Refactory B-Lineage Non-Hodgkin Lymphoma. BLOOD, 126(23).
  
• Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009 Kwong, Y.-L., Anderson, B. O., Advani, R., Kim, W.-S., Levine, A. M., & Lim, S.-T. (2009). Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. LANCET ONCOLOGY, 10(11), 1093–1101.
  
• In Situ Vaccination with TLR9 Agonist Combined with Local Radiation In Mycosis Fungoides: Analysis of Phase I/II Study Kim, Y. H., Gratzinger, D., Harrison, C., Brody, J., Czerwinski, D., Xing, L., … Levy, R. (2010). In Situ Vaccination with TLR9 Agonist Combined with Local Radiation In Mycosis Fungoides: Analysis of Phase I/II Study. BLOOD, 116(21), 130–30.
  
• Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma Illidge, T., Bouabdallah, R., Chen, R., Gopal, A. K., Moskowitz, C. H., Ramchandren, R., … Advani, R. (2015). Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. LEUKEMIA & LYMPHOMA, 56(3), 703–10.
  
• Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin's disease: Mature data in early and advanced stage patients. Horning, S. J., Hoppe, R. T., Advani, R., Warnke, R., Baer, D., Mason, J., & Rosenberg, S. A. (2004). Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin's disease: Mature data in early and advanced stage patients. BLOOD, 104(11), 92A–92A.
  
• Non-Hodgkin's Lymphomas, version 3.2012. Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., … Dwyer, M. A. (2012). Non-Hodgkin's Lymphomas, version 3.2012. Journal of the National Comprehensive Cancer Network , 10(12), 1487–1498.
  
• Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20(+) lymphoid malignancies Roberts, A. W., Advani, R. H., Kahl, B. S., Persky, D., Sweetenham, J. W., Carney, D. A., … Seymour, J. F. (2015). Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20(+) lymphoid malignancies. BRITISH JOURNAL OF HAEMATOLOGY, 170(5), 669–78.
  
• ACR Appropriateness Criteria (R): Follow-Up of Hodgkin's Lymphoma Ng, A., Constine, L. S., Advani, R., Das, P., Flowers, C., Friedberg, J., … Yunes, M. J. (2010). ACR Appropriateness Criteria (R): Follow-Up of Hodgkin's Lymphoma. CURRENT PROBLEMS IN CANCER, 34(3), 211–227.
  
• Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease-the Role of Functional Imaging. Iberri, D. J., Hoppe, R. T., & Advani, R. H. (2015). Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease-the Role of Functional Imaging. Current Treatment Options in Oncology, 16(9), 360-?
  
• Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Aalipour, A., & Advani, R. H. (2014). Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Therapeutic Advances in Hematology, 5(4), 121–33.
  
• A Randomized Phase III Trial of ABVD Vs. Stanford V +/- Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496) Gordon, L. I., Hong, F., Fisher, R. I., Bartlett, N. L., Connors, J. M., Gascoyne, R. D., … Horning, S. J. (2010). A Randomized Phase III Trial of ABVD Vs. Stanford V +/- Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496). BLOOD, 116(21), 185.
  
• CD40 Pathway Activation Status Predicts Response to CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma. Dornan, D., Burington, B., Yue, P., Shi, X., Advani, R., Yu, N., … Ebens, A. J. (2009). CD40 Pathway Activation Status Predicts Response to CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma. BLOOD, 114(22), 1065–65.
  
• Noninvasive detection of clinically relevant copy number alterations in diffuse large B-cell lymphoma. Jin, M. C., Kurtz, D. M., Esfahani, M. S., Scherer, F., Craig, A. F. M., Soo, J., … Alizadeh, A. A. (2017). Noninvasive detection of clinically relevant copy number alterations in diffuse large B-cell lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 35.
  
• Long-Term Follow-up and Analysis of Dose Groups with Ibrutinib in Relapsed Follicular Lymphoma Fowler, N., Boyd, T. E., Sharman, J. P., Smith, S. M., Clow, F., Chu, A. D., & Advani, R. H. (2015). Long-Term Follow-up and Analysis of Dose Groups with Ibrutinib in Relapsed Follicular Lymphoma. BLOOD, 126(23).
  
• Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CT. Lynch, R. C., & Advani, R. H. (2016). Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CT. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, (36), e376–e385.
  
• Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort Evens, A. M., Kanakry, J. A., Sehn, L. H., Kritharis, A., Feldman, T., Kroll, A., … Blum, K. A. (2015). Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort. AMERICAN JOURNAL OF HEMATOLOGY, 90(9), 778–83.
  
• A Phase 1 Study of the Anti-CD37 Antibody-Drug Conjugate AGS67E in Advanced Lymphoid Malignancies. Interim Results Sawas, A., Savage, K. J., Perez, R., Advani, R. H., Butturini, A., Lackey, J., … O'Connor, O. A. (2015). A Phase 1 Study of the Anti-CD37 Antibody-Drug Conjugate AGS67E in Advanced Lymphoid Malignancies. Interim Results. BLOOD, 126(23).
  
• Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2015). Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. Journal of the National Comprehensive Cancer Network , 13(3), 326–362.
  
• A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. de Vos, S., Forero-Torres, A., Ansell, S. M., Kahl, B., Cheson, B. D., Bartlett, N. L., … Advani, R. (2014). A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. Journal of Hematology & Oncology, 7, 44-?
  
• CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma REPLY Advani, R., Volkmer, J.-P., & Chao, M. P. (2019). CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma REPLY. NEW ENGLAND JOURNAL OF MEDICINE, 380(5), 497–98.
  
• Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma. Varma, G., Johnson, T. P., & Advani, R. H. (2016). Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma. Clinical Advances in Hematology & Oncology : H&O, 14(7), 543–54.
  
• Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Advani, R. H., Horning, S. J., Hoppe, R. T., Daadi, S., Allen, J., Natkunam, Y., & Bartlett, N. L. (2014). Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Journal of Clinical Oncology , 32(9), 912–918.
  
• Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496) Gordon, L. I., Hong, F., Fisher, R. I., Bartlett, N. L., Connors, J. M., Gascoyne, R. D., … Horning, S. J. (2013). Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). JOURNAL OF CLINICAL ONCOLOGY, 31(6), 684–91.
  
• Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., Li, S., … Horwitz, S. M. (2015). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of Clinical Oncology , 33(32), 3750–58.
  
• Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Kurtz, D. M., Green, M. R., Bratman, S. V., Scherer, F., Liu, C. L., Kunder, C. A., … Alizadeh, A. A. (2015). Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood, 125(24), 3679–87.
  
• The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study Fowler, N., Sharman, J. P., Smith, S. M., Boyd, T., Grant, B., Kolibaba, K. S., … Advani, R. (2010). The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study. BLOOD, 116(21), 425.
  
• A PHASE I STUDY WITH AN EXPANSION COHORT OF THE COMBINATION OF IPILIMUMAB AND BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A TRIAL OF THE ECOG-ACRIN CANCER RESEARCH GROUP (E4412) Diefenbach, C. S. M., Hong, F., Ambinder, R. F., Cohen, J. B., Robertson, M. J., Fenske, T. S., … Ansell, S. (2016). A PHASE I STUDY WITH AN EXPANSION COHORT OF THE COMBINATION OF IPILIMUMAB AND BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A TRIAL OF THE ECOG-ACRIN CANCER RESEARCH GROUP (E4412). HAEMATOLOGICA, 101, 44–45.
  
• Updates in Treatment Strategies for Hodgkin Lymphoma Advani, R. H. (2019). Updates in Treatment Strategies for Hodgkin Lymphoma. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 17(11), 1411–13.
  
• Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. Torka, P., Kothari, S. K., Sundaram, S., Li, S., Medeiros, L. J., Ayers, E. C., … Hernandez-Ilizaliturri, F. J. (2020). Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. Blood Advances, 4(2), 253–62.
  
• Population pharmacokinetic model of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the treatment of B-cell malignancies Marostica, E., Sukbuntherng, J., Loury, D., Jong, J. D., de Trixhie, X. W., Vermeulen, A., … Poggesi, I. (2014). Population pharmacokinetic model of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the treatment of B-cell malignancies. CANCER RESEARCH, 74(19).
  
• Brentuximab vedotin with chemotherapy for Stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Straus, D. J., Dlugosz-Danecka, M., Alekseev, S., Illes, A., Picardi, M., Lech-Maranda, E., … Gallamini, A. (2020). Brentuximab vedotin with chemotherapy for Stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood.
  
• A Prospective Cohort Study of Patients With Peripheral T-Cell Lymphoma in the United States Carson, K. R., Horwitz, S. M., Pinter-Brown, L. C., Rosen, S. T., Pro, B., Hsi, E. D., … Foss, F. M. (2017). A Prospective Cohort Study of Patients With Peripheral T-Cell Lymphoma in the United States. CANCER, 123(7), 1174–83.
  
• Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy Carreau, N. A., Pail, O., Armand, P., Merryman, R. W., Advani, R. H., Spinner, M. A., … Diefenbach, C. (2018). Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy. BLOOD, 132.
  
• OUTCOMES IN ADOLESCENTS AND YOUNG ADULTS WITH HODGKIN LYMPHOMA TREATED ON US COOPERATIVE GROUP PROTOCOLS: AN ADULT INTERGROUP (E2496) AND CHILDREN'S ONCOLOGY GROUP (COG AHOD0031) COMPARATIVE ANALYSIS Henderson, T. O., Parsons, S. K., Wroblewski, K., Chen, L., Hong, F., Smith, S., … Evens, A. M. (2016). OUTCOMES IN ADOLESCENTS AND YOUNG ADULTS WITH HODGKIN LYMPHOMA TREATED ON US COOPERATIVE GROUP PROTOCOLS: AN ADULT INTERGROUP (E2496) AND CHILDREN'S ONCOLOGY GROUP (COG AHOD0031) COMPARATIVE ANALYSIS. HAEMATOLOGICA, 101, 34–35.
  
• A phase I study of humanized anti-CD40 immunotherapy with SGN-40 in non-Hodgkin's lymphoma. Advani, R. H., Furman, R. R., Rosenblatt, J. D., Younes, A., Forero-Torres, A., Harrop, K. L., … Drachman, J. G. (2005). A phase I study of humanized anti-CD40 immunotherapy with SGN-40 in non-Hodgkin's lymphoma. BLOOD, 106(11), 433A.
  
• Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by (90)Yibritumomab tiuxetan: Ten year follow-up of the phase 2 ECOG-ACRIN study E1499. Smith, M. R., Hong, F., Li, H., Gordon, L. I., Gascoyne, R. D., Paietta, E. M., … Kahl, B. S. (2016). Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by (90)Yibritumomab tiuxetan: Ten year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia.
  
• Value of Surveillance Studies for Patients With Stage I to II Diffuse Large B-Cell Lymphoma in the Rituximab Era. Hiniker, S. M., Pollom, E. L., Khodadoust, M. S., Kozak, M. M., Xu, G., Quon, A., … Hoppe, R. T. (2015). Value of Surveillance Studies for Patients With Stage I to II Diffuse Large B-Cell Lymphoma in the Rituximab Era. International Journal of Radiation Oncology, Biology, Physics, 92(1), 99–106.
  
• Frontline Treatment of CD30+Peripheral T-Cell Lymphomas with Brentuximab Vedotin in Combination with CHP: 3-Year Durability and Survival Follow-up Horwitz, S. M., Shustov, A. R., Forero-Torres, A., Bartlett, N. L., Advani, R., Pro, B., … Fanale, M. A. (2015). Frontline Treatment of CD30+Peripheral T-Cell Lymphomas with Brentuximab Vedotin in Combination with CHP: 3-Year Durability and Survival Follow-up. BLOOD, 126(23).
  
• A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Advani, R., Lebmic, D., Brunvand, M., Chen, A. I., Goy, A., Chang, J. E., … Cheson, B. D. (2012). A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). BLOOD, 120(21).
  
• Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial Advani, R. H., Hong, F., Fisher, R. I., Bartlett, N. L., Robinson, K. S., Gascoyne, R. D., … Horning, S. J. (2015). Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. JOURNAL OF CLINICAL ONCOLOGY, 33(17), 1936–U111.
  
• Resolution of malignant cutaneous lesions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma Advani, R., Pro, B., Kennedy, D., & Fanale, M. (2012). Resolution of malignant cutaneous lesions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 66(4), AB4.
  
• Acquired mutations associated with ibrutinib resistance in Waldenstrom Macroglobulinemia. Xu, L., Tsakmaklis, N., Yang, G., Chen, J. G., Liu, X., Demos, M., … Treon, S. P. (2017). Acquired mutations associated with ibrutinib resistance in Waldenstrom Macroglobulinemia. Blood.
  
• Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Morschhauser, F., Flinn, I., Advani, R. H., Diefenbach, C. S., Kolibaba, K., Press, O. W., … Sharman, J. P. (2014). Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. BLOOD, 124(21).
  
• Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy Cheson, B. D., Ansell, S., Schwartz, L., Gordon, L. I., Advani, R., Jacene, H. A., … Armand, P. (2016). Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. BLOOD, 128(21), 2489–96.
  
• Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., … Shustov, A. R. (2014). Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. BLOOD, 124(21).
  
• Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Fayad, L., Ansell, S. M., Advani, R., Coiffier, B., Stuart, R., Bartlett, N. L., … Drachman, J. G. (2015). Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leukemia & Lymphoma, 56(9), 2569–78.
  
• A gene signature predicts sensitivity to the partial CD40 agonist, dacetuzumab (SGN-40), in patients with diffuse large B-cell lymphoma Burington, B., Advani, R., Shi, X., Yue, P., Lau, J., Yu, S.-F., … Dornan, D. (2009). A gene signature predicts sensitivity to the partial CD40 agonist, dacetuzumab (SGN-40), in patients with diffuse large B-cell lymphoma. CANCER RESEARCH, 69.
  
• A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Horwitz, S. M., Pinter-Brown, L. C., Rosen, S. T., Pro, B., Hsi, E. D., Federico, M., … Foss, F. M. (2016). A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer.
  
• Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation Aghighi, M., Theruvath, A. J., Pareek, A., Pisani, L. L., Alford, R., Muehe, A. M., … Daldrup-Link, H. E. (2018). Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation. CLINICAL CANCER RESEARCH, 24(17), 4110–18.
  
• Brentuximab Vedotin Monotherapy in DLBCL Patients with Undetectable CD30: Preliminary Results from a Phase 2 Study Bartlett, N. L., Smith, M. R., Advani, R., Feldman, T., Savage, K. J., Palanca-Wessels, M. C., & Siddiqi, T. (2014). Brentuximab Vedotin Monotherapy in DLBCL Patients with Undetectable CD30: Preliminary Results from a Phase 2 Study. BLOOD, 124(21).
  
• Risk-adapted therapy for advanced-stage Hodgkin lymphoma Spinner, M. A., & Advani, R. H. (2018). Risk-adapted therapy for advanced-stage Hodgkin lymphoma. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 200–206.
  
• NCCN Guidelines (R) Insights Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017 Featured Updates to the NCCN Guidelines Wierda, W. G., Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2017). NCCN Guidelines (R) Insights Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(3), 293–311.
  
• Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study Wang, M., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., … Blum, K. A. (2014). Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study. BLOOD, 124(21).
  
• Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity Salzberg, M. P., Maragulia, J. C., Press, O. W., Habermann, T. M., Vose, J. M., Bast, M., … Lossos, I. S. (2012). Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity. BLOOD, 120(21).
  
• Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas. Jagadeesh, D., Horwitz, S. M., Bartlett, N. L., Advani, R. H., Jacobsen, E. D., Duvic, M., … Kim, Y. H. (2019). Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas. JOURNAL OF CLINICAL ONCOLOGY, 37(15).
  
• Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry Bartlett, N. L., Smith, M. R., Siddiqi, T., Advani, R. H., O'Connor, O. A., Sharman, J. P., … Jacobsen, E. D. (2017). Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. LEUKEMIA & LYMPHOMA, 58(7), 1607–16.
  
• Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma Evens, A. M., Advani, R. H., Helenowski, I. B., Fanale, M., Smith, S. M., Jovanovic, B. D., … Hamlin, P. A. (2018). Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 36(30), 3015-+.
  
• A phase I study of ZD 1839 (Iressa) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) in advanced solid malignancies Fisher, G. A., Cho, C. D., Halsey, J. Z., Advani, R. H., Yuen, A. R., Lum, B. L., & Sikic, B. I. (2002). A phase I study of ZD 1839 (Iressa) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) in advanced solid malignancies. Presented at the 14th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics, FRANKFURT,GERMANY: ELSEVIER SCI LTD.
  
• Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL. Kurtz, D. M., Green, M. R., Bratman, S. V., Liu, C.-L., Glover, C., Keane, C., … Alizadeh, A. A. (2014). Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL. JOURNAL OF CLINICAL ONCOLOGY, 32(15).
  
• Non-Hodgkin's Lymphomas, Version 1.2013 Featured Updates to the NCCN Guidelines Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., … Naganuma, M. (2013). Non-Hodgkin's Lymphomas, Version 1.2013 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(3), 257–73.
  
• A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia Furman, R. R., Eradat, H., DiRienzo, C. G., Hayman, S. R., Hofmeister, C. C., Avignon, N. A., … Lin, T. S. (2011). A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia. BLOOD, 118(21), 1581–81.
  
• Population pharmacokinetic-pharmacodynamic (PKPD) modeling of ibrutinib in patients with B-cell malignancies. Poggesi, I., Sardu, M. L., Marostica, E., Sukbuntherng, J., Chang, B. Y., de Jong, J., … Wang, M. (2015). Population pharmacokinetic-pharmacodynamic (PKPD) modeling of ibrutinib in patients with B-cell malignancies. CLINICAL CANCER RESEARCH, 21.
  
• The landscape of new drugs in lymphoma. Younes, A., Ansell, S., Fowler, N., Wilson, W., de Vos, S., Seymour, J., … Vose, J. (2016). The landscape of new drugs in lymphoma. Nature Reviews. Clinical Oncology.
  
• A first in human experience of the anti-CD37 antibody-drug conjugate AGS67E in lymphoid malignancies. Sawas, A., Savage, K. J., Perez, R. P., Advani, R. H., Melhem-Bertrandt, A., Lackey, J., … O'Connor, O. A. (2016). A first in human experience of the anti-CD37 antibody-drug conjugate AGS67E in lymphoid malignancies. JOURNAL OF CLINICAL ONCOLOGY, 34(15).
  
• How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1 h: the Stanford Approach. Muehe, A. M., Theruvath, A. J., Lai, L., Aghighi, M., Quon, A., Holdsworth, S. J., … Daldrup-Link, H. E. (2017). How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1 h: the Stanford Approach. Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging.
  
• Updated phase 2 safety analysis of prevalence of infection, diarrhea, and bleeding with ibrutinib over time in previously treated mantle cell lymphoma Stilgenbauer, S., Rule, S., Wang, M. L., Martin, P., Auer, R., Kahl, B. S., … Blum, K. A. (2014). Updated phase 2 safety analysis of prevalence of infection, diarrhea, and bleeding with ibrutinib over time in previously treated mantle cell lymphoma. ONCOLOGY RESEARCH AND TREATMENT, 37, 34–35.
  
• PHASE 2 STUDY OF IBRUTINIB IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: UPDATED SAFETY ANALYSIS ON PREVALENCE OF INFECTION, DIARRHEA, AND BLEEDING OVER TIME Rule, S., Wang, M. L., Martin, P., Auer, R., Kahl, B. S., Jurczak, W., … Blum, K. A. (2014). PHASE 2 STUDY OF IBRUTINIB IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: UPDATED SAFETY ANALYSIS ON PREVALENCE OF INFECTION, DIARRHEA, AND BLEEDING OVER TIME. HAEMATOLOGICA, 99, 150.
  
• INTERNATIONAL EXTRANODAL NK/T-CELL LYMPHOMA PROJECT: PROGNOSTIC FACTORS IN THE ERA OF NONANTHRACYCLINE-BASED TREATMENT Kim, S. J., Park, Y., Chang, M. H., Oh, S. Y., Kwak, J. Y., Yang, D. H., … Kim, W. S. (2015). INTERNATIONAL EXTRANODAL NK/T-CELL LYMPHOMA PROJECT: PROGNOSTIC FACTORS IN THE ERA OF NONANTHRACYCLINE-BASED TREATMENT. HAEMATOLOGICA, 100, 5.
  
• Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression Jacobsen, E. D., Sharman, J. P., Oki, Y., Advani, R. H., Winter, J. N., Bello, C. M., … Bartlett, N. L. (2015). Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. BLOOD, 125(9), 1394–1402.
  
• The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma. Fowler, N. H., Nastoupil, L., De Vos, S., Knapp, M., Flinn, I. W., Chen, R., … Palomba, M. L. (2020). The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma. British Journal of Haematology.
  
• IBRUTINIB IN PREVIOUSLY TREATED PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA IS HIGHLY ACTIVE, PRODUCES DURABLE RESPONSES, AND IS IMPACTED BY MYD88 AND CXCR4 MUTATION STATUS Treon, S., Tripsas, C., Meid, K., Warren, D., Varma, G., Green, R., … Advani, R. (2015). IBRUTINIB IN PREVIOUSLY TREATED PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA IS HIGHLY ACTIVE, PRODUCES DURABLE RESPONSES, AND IS IMPACTED BY MYD88 AND CXCR4 MUTATION STATUS. HAEMATOLOGICA, 100, 311.
  
• Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes Pfeifer, M., Zheng, B., Erdmann, T., Koeppen, H., McCord, R., Grau, M., … Lenz, G. (2015). Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. LEUKEMIA, 29(7), 1578–86.
  
• Histologic subtypes of breast cancer following radiotherapy for Hodgkin lymphoma. Horst, K. C., Hancock, S. L., OGNIBENE, G., Chen, C., Advani, R. H., Rosenberg, S. A., … Hoppe, R. T. (2014). Histologic subtypes of breast cancer following radiotherapy for Hodgkin lymphoma. Annals of Oncology , 25(4), 848–51.
  
• ACR appropriateness criteria follow-up of Hodgkin lymphoma. Ha, C. S., Hodgson, D. C., Advani, R., Dabaja, B. S., Dhakal, S., Flowers, C. R., … Constine, L. S. (2014). ACR appropriateness criteria follow-up of Hodgkin lymphoma. Journal of the American College of Radiology , 11(11), 1026–1033 e3.
  
• Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. Merryman, R. W., Carreau, N. A., Advani, R. H., Spinner, M. A., Herrera, A. F., Chen, R., … Armand, P. (2020). Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma. The Oncologist.
  
• Utility of Routine Surveillance Laboratory Testing in Detecting Relapse in Patients With Classic Hodgkin Lymphoma in First Remission: Results From a Large Single-Institution Study. Lynch, R. C., Sundaram, V., Desai, M., Henry, S., Wood, D., Daadi, S., … Advani, R. (2020). Utility of Routine Surveillance Laboratory Testing in Detecting Relapse in Patients With Classic Hodgkin Lymphoma in First Remission: Results From a Large Single-Institution Study. JCO Oncology Practice, JOP1900733.
  
• First-in-human study assessing safety and tolerability of REGN1979, a novel CD20xCD3 bispecific antibody, in patients with CD20+B-cell malignancies previously treated with anti-CD20 therapy. Brownstein, C. M., Adriaens, L., Bannerji, R., Chavez, J. C., Levy, R., Ansell, S. M., … Kohrt, H. E. (2015). First-in-human study assessing safety and tolerability of REGN1979, a novel CD20xCD3 bispecific antibody, in patients with CD20+B-cell malignancies previously treated with anti-CD20 therapy. JOURNAL OF CLINICAL ONCOLOGY, 33(15).
  
• A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors de Vos, S., Forero-Torres, A., Ansell, S. M., Kahl, B., Cheson, B. D., Bartlett, N. L., … Advani, R. (2014). A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. JOURNAL OF HEMATOLOGY & ONCOLOGY, 7.
  
• A phase I trial of oblimersen and gemcitabine in refractory and advanced malignancies Fisher, G., Advani, R., Wakelee, H., Jacobs, C., Gladysheva, K., Fitzgerald, A. M., & Sikic, B. (2005). A phase I trial of oblimersen and gemcitabine in refractory and advanced malignancies. JOURNAL OF CLINICAL ONCOLOGY, 23(16), 234S–234S.
  
• Phase I/II study of intratumoral injection of SD-101, an immunostimulatory CpG, and intratumoral injection of ipillumumab, an anti-CTLA-4 monoclonal antibody, in combination with local radiation in low-grade B-cell lymphomas. Khodadoust, M. S., Chu, M. P., Czerwinski, D., McDonald, K., Long, S., Kohrt, H. E., … Levy, R. (2015). Phase I/II study of intratumoral injection of SD-101, an immunostimulatory CpG, and intratumoral injection of ipillumumab, an anti-CTLA-4 monoclonal antibody, in combination with local radiation in low-grade B-cell lymphomas. JOURNAL OF CLINICAL ONCOLOGY, 33(15).
  
• Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031) Comparative Analysis Henderson, T. O., Parsons, S. K., Wroblewski, K., Chen, L., Hong, F., Smith, S. M., … Evens, A. M. (2015). Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031) Comparative Analysis. BLOOD, 126(23).
  
• Brentuximab Vedotin in Combination with RCHOP As Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak, C. A., Farber, C. M., Budde, L. E., Ansell, S. M., Advani, R., Holkova, B., … Bartlett, N. L. (2014). Brentuximab Vedotin in Combination with RCHOP As Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study. BLOOD, 124(21).
  
• Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88(L265P) Mutation Lynch, R. C., & Advani, R. H. (2017). Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88(L265P) Mutation. CASE REPORTS IN ONCOLOGY, 10(3), 813–18.
  
• Value of surveillance studies for patients (pts) with stage I-II diffuse large B-cell lymphoma (DLBCL) in the rituximab (R) era. Hiniker, S. M., Pollom, E. L., Khodadoust, M. S., Kozak, M. M., Advani, R. H., & Hoppe, R. T. (2014). Value of surveillance studies for patients (pts) with stage I-II diffuse large B-cell lymphoma (DLBCL) in the rituximab (R) era. JOURNAL OF CLINICAL ONCOLOGY, 32(15).
  
• Efficacy and Safety of Single-Agent Ibrutinib in Patients with Mantle Cell Lymphoma Who Progressed after Bortezomib Therapy Wang, M., Goy, A., Martin, P., Ramchandren, R., Alexeeva, J., Popat, R., … Rule, S. (2014). Efficacy and Safety of Single-Agent Ibrutinib in Patients with Mantle Cell Lymphoma Who Progressed after Bortezomib Therapy. BLOOD, 124(21).
  
• A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results Jacobsen, E. D., Advani, R. H., Oki, Y., Sharman, J., Horwitz, S. M., Forero-Torres, A., … Bartlett, N. L. (2012). A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results. BLOOD, 120(21).
  
• The role of interim 18F-FDG PET/CT in DLBCL patients: SUV max, SUV mean and SUV peak as predictive metabolic parameters of prognosis Baratto, L., Wu, F., Minamimoto, R., Sabile, J., Advani, R., & Mittra, E. (2016). The role of interim 18F-FDG PET/CT in DLBCL patients: SUV max, SUV mean and SUV peak as predictive metabolic parameters of prognosis. JOURNAL OF NUCLEAR MEDICINE, 57.
  
• Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas Fanale, M. A., Horwitz, S. M., Forero-Torres, A., Bartlett, N. L., Advani, R. H., Pro, B., … Shustov, A. R. (2018). Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. BLOOD, 131(19), 2120–24.
  
• Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Macroglobulinemia Castillo, J. J., Gustine, J., Meid, K., Dubeau, T., Keezer, A., Allan, J. N., … Treon, S. P. (2018). Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Macroglobulinemia. BLOOD, 132.
  
• Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL): Management in the Modern Era King, M., Donaldson, S., Link, M., Advani, R., & Hoppe, R. (2014). Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL): Management in the Modern Era. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90, S67–S68.
  
• Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine Advani, R., Horwitz, S., Zelenetz, A., & Horning, S. J. (2007). Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine. LEUKEMIA & LYMPHOMA, 48(3), 521–25.
  
• Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma LaCasce, A. S., Bociek, R. G., Sawas, A., Caimi, P., Agura, E., Matous, J., … Advani, R. (2018). Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. BLOOD, 132(1), 40–48.
  
• A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma: CC-122-DLBCL-001 Ribrag, V., Chavez, J. C., Kaplan, J. B., Vitolo, U., Chandler, J. C., Santoro, A., … Kuruvilla, J. (2016). A Phase 1b, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma: CC-122-DLBCL-001. BLOOD, 128(22).
  
• Diffuse Large B-Cell Lymphoma Version 1.2016 Clinical Practice Guidelines in Oncology Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2016). Diffuse Large B-Cell Lymphoma Version 1.2016 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(2), 196–231.
  
• Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) Forero-Torres, A., Berryman, R. B., Advani, R. H., Bartlett, N. L., Chen, R. W., Fanale, M. A., … Matous, J. (2011). Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL). BLOOD, 118(21), 1585–86.
  
• Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Duncavage, E., Advani, R. H., Agosti, S., Foulis, P., Gibson, C., Kang, L., … Wilson, C. (2016). Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 140(11), 1225–27.
  
• Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: Preliminary results from a phase II study. Advani, R., Oki, Y., Shustov, A. R., Grove, L. E., & Bartlett, N. (2012). Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: Preliminary results from a phase II study. JOURNAL OF CLINICAL ONCOLOGY, 30(15).
  
• Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F) Hong, F., Thanarajasingam, G., Ansell, S. M., Ambinder, R. F., Cohen, J. B., Robertson, M., … Diefenbach, C. (2018). Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F). BLOOD, 132.
  
• A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. Binkley, M. S., Hiniker, S. M., Wu, S., Natkunam, Y., Mittra, E. S., Advani, R. H., & Hoppe, R. T. (2016). A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. Leukemia & Lymphoma, 57(3), 604–8.
  
• Diffuse Large B-Cell Lymphoma Version 1.2016. Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2016). Diffuse Large B-Cell Lymphoma Version 1.2016. Journal of the National Comprehensive Cancer Network , 14(2), 196–231.
  
• Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy LaCasce, A., Bociek, R. G., Matous, J., Sawas, A., Caimi, P., Ansell, S. M., … Advani, R. (2014). Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy. BLOOD, 124(21).
  
• T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment. Casulo, C., O'Connor, O., Shustov, A., Fanale, M., Friedberg, J. W., Leonard, J. P., … Horwitz, S. (2017). T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment. Journal of the National Cancer Institute, 109(2).
  
• International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Younes, A., HILDEN, P., Coiffier, B., Hagenbeek, A., Salles, G., Wilson, W., … Seshan, V. E. (2017). International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Annals of Oncology .
  
• Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD3O-Positive Mature T-Cell and NK-Cell Lymphomas Fanale, M. A., Shustov, A. R., Forero-Torres, A., Bartlett, N. L., Advani, R. H., Pro, B., … Horwitz, S. M. (2012). Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD3O-Positive Mature T-Cell and NK-Cell Lymphomas. BLOOD, 120(21).
  
• The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imid (R) Continuation (BIONIC) Study Baratto, L., Jegede, O., Hong, F., Habermann, T. M., Advani, R., Gascoyne, R. D., … Evens, A. M. (2018). The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imid (R) Continuation (BIONIC) Study. BLOOD, 132.
  
• Results of a prospective phase II trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin's disease (NLPHD) Horning, S. J., Bartlett, N. L., Breslin, S., Advani, R. H., Hoppe, R. T., Ekstrand, B. C., & Lucas, J. B. (2007). Results of a prospective phase II trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin's disease (NLPHD). BLOOD, 110(11), 198A.
  
• Hodgkin Lymphoma Version 1.2017 Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Bello, C. M., … Sundar, H. (2017). Hodgkin Lymphoma Version 1.2017. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 15(5), 608–38.
  
• A prospective trial of involved field radiation (IFRT) plus chemotherapy compared to extended field (EFRT) radiation for favorable Hodgkin disease: Survival differences and implications of mature follow-up for current combined modality therapy Horning, S. J., Hoppe, R. T., Advani, R. H., Breslin, S., Allen, J., Hancock, S. L., & Rosenberg, S. A. (2007). A prospective trial of involved field radiation (IFRT) plus chemotherapy compared to extended field (EFRT) radiation for favorable Hodgkin disease: Survival differences and implications of mature follow-up for current combined modality therapy. JOURNAL OF CLINICAL ONCOLOGY, 25(18).
  
• Analysis of Breast Cancer Subtypes in Women who Develop Breast Cancer following Mantle Irradiation for Hodgkin's Disease Horst, K. C., Hancock, S., Advani, R., Horning, S., Rosenberg, S., & Hoppe, R. T. (2010). Analysis of Breast Cancer Subtypes in Women who Develop Breast Cancer following Mantle Irradiation for Hodgkin's Disease. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S206–S207.
  
• Cancer Vaccines and T Cell Therapy (vol 19, pg S97, 2013) Rezvani, K., Brody, J. D., Kohrt, H. E., Logan, A. C., Advani, R., Czerwinski, D. K., … Barrett, J. (2013). Cancer Vaccines and T Cell Therapy (vol 19, pg S97, 2013). BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(10), 1530.
  
• Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Horwitz, S., O'Connor, O. A., Pro, B., Illidge, T., Fanale, M., Advani, R., … Zinzan, P. L. (2019). Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. LANCET, 393(10168), 229–40.
  
• Enhanced bioavailability of oral paclitaxel by valspodar (PSC 833), an inhibitor of small bowel P-glycoprotein and cytochrome P450. Sikic, B. I., Advani, R., Fisher, G. A., Halsey, J., Cohen, P., & Lum, B. L. (2000). Enhanced bioavailability of oral paclitaxel by valspodar (PSC 833), an inhibitor of small bowel P-glycoprotein and cytochrome P450. CLINICAL CANCER RESEARCH, 6, 4580S.
  
• Clinical Impact of the 2016 Update to the WHO Lymphoma Classification (vol 18, 45, 2017) Lynch, R. C., Gratzinger, D., & Advani, R. H. (2017). Clinical Impact of the 2016 Update to the WHO Lymphoma Classification (vol 18, 45, 2017). CURRENT TREATMENT OPTIONS IN ONCOLOGY, 18(10), 60.
  
• A PHASE I TRIAL OF BTK INHIBITOR PCI-32765 IN PATIENTS WITH RELAPSED NON-HODGKIN'S LYMPHOMA: EVIDENCE OF ANTITUMOR ACTIVITY Fowler, N., Sharman, J., Smith, S., Pollyea, D., Boyd, T., Grant, B., … Advani, R. (2010). A PHASE I TRIAL OF BTK INHIBITOR PCI-32765 IN PATIENTS WITH RELAPSED NON-HODGKIN'S LYMPHOMA: EVIDENCE OF ANTITUMOR ACTIVITY. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95, 371.
  
• Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma Ramchandren, R., Advani, R. H., Ansell, S. M., Bartlett, N. L., Chen, R., Connors, J. M., … Straus, D. J. (2019). Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. CLINICAL CANCER RESEARCH, 25(6), 1718–26.
  
• Schedule and concentration dependent increase of coagulation times and complement split products in phase I/II trials of an antisense oligonucleotide targeted to protein kinase C-alpha(ISIS 3521/ISI641A). Advani, R., Lum, B. L., Fisher, G. A., Grant, P., Halsey, J., Yuen, A., … Sikic, B. I. (1999). Schedule and concentration dependent increase of coagulation times and complement split products in phase I/II trials of an antisense oligonucleotide targeted to protein kinase C-alpha(ISIS 3521/ISI641A). BLOOD, 94(10), 94B.
  
• Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study Yasenchak, C. A., Halwani, A., Advani, R., Ansell, S., Budde, L. E., Burke, J. M., … Bartlett, N. L. (2015). Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study. BLOOD, 126(23).
  
• Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation. Spinner, M. A., Advani, R. H., Hoppe, R. T., Lowsky, R., & Muffly, L. S. (2018). Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation. Blood Advances, 2(13), 1547–50.
  
• Randomized Phase III Trial Comparing ABVD plus Radiotherapy and the Stanford V.Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A-Subset Analysis of the US Intergroup Trial E2496 Advani, R., Hong, F., Fisher, R. I., Bartlett, N. L., Robinson, S., Gascoyne, R. D., … Horning, S. J. (2010). Randomized Phase III Trial Comparing ABVD plus Radiotherapy and the Stanford V.Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A-Subset Analysis of the US Intergroup Trial E2496. BLOOD, 116(21), 185–86.
  
• Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Morschhauser, F., Flinn, I. W., Advani, R., Sehn, L. H., Diefenbach, C., Kolibaba, K., … Sharman, J. (2019). Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). The Lancet. Haematology.
  
• Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Pro, B., Advani, R. H., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., … Shustov, A. R. (2012). Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. BLOOD, 120(21).
  
• Elucidation of distinct mutational patterns between diffuse large B cell lymphoma subtypes utilizing circulating tumor DNA. Soo, J., Kurtz, D. M., Scherer, F., Craig, A. F. M., Jin, M. C., Westin, J. R., … Alizadeh, A. A. (2017). Elucidation of distinct mutational patterns between diffuse large B cell lymphoma subtypes utilizing circulating tumor DNA. JOURNAL OF CLINICAL ONCOLOGY, 35.
  
• BRENTUXIMAB VEDOTIN PLUS BENDAMUSTINE AS A SALVAGE TREATMENT REGIMEN FOR PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA LaCasce, A., Bociek, G., Sawas, A., Caimi, P., Agura, E., Matous, J., … Advani, R. (2016). BRENTUXIMAB VEDOTIN PLUS BENDAMUSTINE AS A SALVAGE TREATMENT REGIMEN FOR PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA. HAEMATOLOGICA, 101, 45–46.
  
• SEQUENTIAL THERAPY WITH BRENTUXIMAB VEDOTIN IN NEWLY DIAGNOSED PATIENTS WITH SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA Fanale, M., Advani, R., Bartlett, N. L., Davies, A., Illidge, T., Kennedy, D. A., & Shustov, A. R. (2012). SEQUENTIAL THERAPY WITH BRENTUXIMAB VEDOTIN IN NEWLY DIAGNOSED PATIENTS WITH SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA. ANNALS OF ONCOLOGY, 23, 348.
  
• Attitudes and beliefs towards surviorship issues in Hodgkin's disease (HD). Results of focus group discussions with patients treated at stanford university Advani, R., Rosenberg, S., Talreja, N., Hoppe, R., & Horning, S. (2008). Attitudes and beliefs towards surviorship issues in Hodgkin's disease (HD). Results of focus group discussions with patients treated at stanford university. Presented at the 10th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND: OXFORD UNIV PRESS.
  
• EFFICACY AND TOLERABILITY OF ABVD AND STANFORD V FOR ELDERLY ADVANCED-STAGE HODGKIN LYMPHOMA (HL): ANALYSIS FROM THE PHASE III RANDOMIZED US INTERGROUP TRIAL E2496 Evens, A. M., Hong, F., Gordon, L. I., Fisher, R. I., Bartlett, N., Connors, J. M., … Horning, S. J. (2011). EFFICACY AND TOLERABILITY OF ABVD AND STANFORD V FOR ELDERLY ADVANCED-STAGE HODGKIN LYMPHOMA (HL): ANALYSIS FROM THE PHASE III RANDOMIZED US INTERGROUP TRIAL E2496. ANNALS OF ONCOLOGY, 22, 117–18.
  
• A phase I trial of ISIS 3521 (IS1641A), an antisense inhibitor of protein kinase C alpha, combined with carboplatin and paclitaxel in patients with cancer. Yuen, A., Sikic, B. I., Advani, R., Fisher, G., Halsey, J., Lum, B., … Dorr, A. (1999). A phase I trial of ISIS 3521 (IS1641A), an antisense inhibitor of protein kinase C alpha, combined with carboplatin and paclitaxel in patients with cancer. CLINICAL CANCER RESEARCH, 5, 3846S–3847S.
  
• Ibrutinib-Associated Rash: Single-Center Experience of Clinicopathologic Features and Management Iberri, D. J., Kwong, B., Stevens, L., Coutre, S. E., Kim, J., Sabile, J., & Advani, R. H. (2015). Ibrutinib-Associated Rash: Single-Center Experience of Clinicopathologic Features and Management. BLOOD, 126(23).
  
• Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS) Morschhauser, F., Flinn, I. W., Advani, R., Sehn, L. H., Diefenbach, C., Kolibaba, K., … Sharman, J. (2019). Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). LANCET HAEMATOLOGY, 6(5), E254–E265.
  
• Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2018). Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 36(28), 2845-+.
  
• Response to brentuximab vedotin plus CHP according to CD30 expression in the ECHELON-2 trial Illidge, T., Horwitz, S., Iyer, S., Bartlett, N., Kim, W. S., Belada, D., … Advani, R. (2020). Response to brentuximab vedotin plus CHP according to CD30 expression in the ECHELON-2 trial. BRITISH JOURNAL OF HAEMATOLOGY, 189, 111–12.
  
• Frontline Therapy of Nodular Lymphocyte Predominant Hodgkin Lymphoma with Rituximab: The Stanford University Experience Advani, R. H., Horning, S. J., Hoppe, R. T., Daadi, S., Allen, J., Natkunam, Y., … Bartlett, N. L. (2011). Frontline Therapy of Nodular Lymphocyte Predominant Hodgkin Lymphoma with Rituximab: The Stanford University Experience. BLOOD, 118(21), 1154.
  
• Cardiac Toxicity Associated with the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) in Combination with CROP (A-CHOP) Chemotherapy for Peripheral T Cell Lymphoma (PTCL): The ECOG 2404 Trial. Advani, R. H., Hong, F., Ganjoo, K. N., Manola, J. B., Swinnen, L. J., Habermann, T. M., & Horning, S. J. (2009). Cardiac Toxicity Associated with the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) in Combination with CROP (A-CHOP) Chemotherapy for Peripheral T Cell Lymphoma (PTCL): The ECOG 2404 Trial. BLOOD, 114(22), 667.
  
• Stage I/II Hodgkin's disease: Comparison of outcomes of patients with bulky mediastinal disease versus other risk factors; the Stanford V experience Advani, R. H., Hoppe, R. T., Rosenberg, S. A., & Horning, S. J. (2007). Stage I/II Hodgkin's disease: Comparison of outcomes of patients with bulky mediastinal disease versus other risk factors; the Stanford V experience. BLOOD, 110(11), 685A–685A.
  
• Noninvasive molecular subtyping and risk stratification of DLBCL. Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2016). Noninvasive molecular subtyping and risk stratification of DLBCL. JOURNAL OF CLINICAL ONCOLOGY, 34(15).
  
• 2 Gy?×?2 for palliative treatment of mantle cell lymphoma. White, E. C., Advani, R., & Hoppe, R. T. (2016). 2 Gy?×?2 for palliative treatment of mantle cell lymphoma. Leukemia & Lymphoma, 57(9), 2219–21.
  
• Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma Moskowitz, C. H., Forero-Torres, A., Shah, B. D., Advani, R., Hamlin, P., Kim, S., … Fanale, M. A. (2014). Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma. BLOOD, 124(21).
  
• A Phase 1/2 Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma in the First Salvage Setting: Interim Results LaCasce, A., Sawas, A., Bociek, R. G., Ansell, S., Vose, J., O'Meara, M., & Advani, R. (2014). A Phase 1/2 Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma in the First Salvage Setting: Interim Results. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20(2), S161.
  
• Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial Foss, F. M., Sjak-Shie, N. N., Goy, A., Advani, R., & Jacobsen, E. D. (2010). Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial. JOURNAL OF CLINICAL ONCOLOGY, 28(15).
  
• No Utility of Routine Laboratory Testing during Surveillance in Detecting Relapse in Patients with Classic Hodgkin Lymphoma in First Remission Lynch, R. C., Sundaram, V., Desai, M., Henry, S., Wood, D., Daadi, S., … Advani, R. (2018). No Utility of Routine Laboratory Testing during Surveillance in Detecting Relapse in Patients with Classic Hodgkin Lymphoma in First Remission. BLOOD, 132.
  
• A phase II study of derdleukin diftitox (Ontak (R)) with CHOP chemotherapy in patients with newly-diagnosed aggressive T-cell lymphomas, the CONCEPT trial: Interim analysis. Foss, F. M., Sjak-Shie, N., Goy, A., Advani, R., Jacobsen, E., & Acosta, M. (2006). A phase II study of derdleukin diftitox (Ontak (R)) with CHOP chemotherapy in patients with newly-diagnosed aggressive T-cell lymphomas, the CONCEPT trial: Interim analysis. BLOOD, 108(11), 696A–697A.
  
• SGN-40 (Anti-huCD40 mAb) monotherapy induces durable objective responses in patients with relapsed aggressive non-Hodgkin's lymphoma: Evidence of antitumor activity from a phase I study. Advani, R., Forero-Torres, A., Furman, R. R., Rosenblatt, J. D., Younes, A., Shankles, B., … Drachman, J. G. (2006). SGN-40 (Anti-huCD40 mAb) monotherapy induces durable objective responses in patients with relapsed aggressive non-Hodgkin's lymphoma: Evidence of antitumor activity from a phase I study. BLOOD, 108(11), 209A.
  
• Phase I trial of SNS-595 in patients (pts) with advanced malignancies. Advani, R., Gordon, M., Hurwitz, H., Mendelson, D., Wakelee, H., Ebbinghaus, S., … Adelman, D. (2005). Phase I trial of SNS-595 in patients (pts) with advanced malignancies. CLINICAL CANCER RESEARCH, 11(24), 9056S.
  
• Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Pro, B., Advani, R. H., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., … Shustov, A. R. (2016). Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. BLOOD, 128(22).
  
• Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma Herrera, A. F., Bartlett, N. L., Ramchandren, R., Vose, J. M., Moskowitz, A. J., Feldman, T. A., … Advani, R. H. (2016). Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. BLOOD, 128(22).
  
• Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412) Diefenbach, C. S., Hong, F., Cohen, J. B., Robertson, M. J., Ambinder, R. F., Fenske, T. S., … Ansell, S. (2015). Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412). BLOOD, 126(23).
  
• Prospective multicenter comparison of early interim F-18-FLT PET/CT versus F-18-FDG PET/CT Minamimoto, R., Fayad, L., Advani, R., Vose, J., Macapinlac, H., Meza, J., … Quon, A. (2015). Prospective multicenter comparison of early interim F-18-FLT PET/CT versus F-18-FDG PET/CT. JOURNAL OF NUCLEAR MEDICINE, 56(3).
  
• Response to A+CHP by CD30 expression in the ECHELON-2 trial. Advani, R. H., Horwitz, S. M., Iyer, S. P., Bartlett, N. L., Kim, W. S., Tilly, H., … Illidge, T. (2019). Response to A+CHP by CD30 expression in the ECHELON-2 trial. JOURNAL OF CLINICAL ONCOLOGY, 37(15).
  
• Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL). Bartlett, N. L., Farber, C. M., Yasenchak, C. A., Ansell, S. M., Advani, R. H., Knapp, M. H., … Halwani, A. S. (2015). Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL). JOURNAL OF CLINICAL ONCOLOGY, 33(15).
  
• Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era Diefenbach, C. S., Li, H., Hong, F., Gordon, L. I., Fisher, R. I., Bartlett, N. L., … Advani, R. H. (2015). Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. BRITISH JOURNAL OF HAEMATOLOGY, 171(4), 530–38.
  
• Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Byrd, J. C., Smith, S., Wagner-Johnston, N., Sharman, J., Chen, A. I., Advani, R., … Flinn, I. W. (2019). Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget, 10(38), 3827–30.
  
• Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. Rosenwald, A., Bens, S., Advani, R., Barrans, S., Copie-Bergman, C., Elsensohn, M.-H., … Maucort-Boulch, D. (2019). Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1900743.
  
• ABBREVIATED 8 WK CHEMOTHERAPY (CT) plus INVOLVED NODE RADIOTHERAPY (INRT) FOR NON-BULKY STAGE I-II HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE STANFORD G5 STUDY Advani, R. H., Horning, S. J., Jonathan, E., Daadi, S., Allen, J., Rosenberg, S. A., & Hoppe, R. T. (2011). ABBREVIATED 8 WK CHEMOTHERAPY (CT) plus INVOLVED NODE RADIOTHERAPY (INRT) FOR NON-BULKY STAGE I-II HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE STANFORD G5 STUDY. ANNALS OF ONCOLOGY, 22, 179.
  
• ACR Appropriateness Criteria® Hodgkin Lymphoma-Unfavorable Clinical Stage I and II. Roberts, K. B., Younes, A., Hodgson, D. C., Advani, R., Dabaja, B. S., Dhakal, S., … Constine, L. S. (2016). ACR Appropriateness Criteria® Hodgkin Lymphoma-Unfavorable Clinical Stage I and II. American Journal of Clinical Oncology, 39(4), 384–95.
  
• THE BTK INHIBITOR PCI-32765 IS HIGHLY ACTIVE AND WELL TOLERATED IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES: FINAL RESULTS FROM A PHASE I STUDY Advani, R. H., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B. W., Kolibaba, K. S., … Fowler, N. H. (2011). THE BTK INHIBITOR PCI-32765 IS HIGHLY ACTIVE AND WELL TOLERATED IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES: FINAL RESULTS FROM A PHASE I STUDY. ANNALS OF ONCOLOGY, 22, 135.
  
• Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2016). Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. SCIENCE TRANSLATIONAL MEDICINE, 8(364).
  
• Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. LaCasce, A. S., Bociek, R. G., Sawas, A., Caimi, P., Agura, E., Matous, J., … Advani, R. (2020). Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. British Journal of Haematology.
  
• PRELIMINARY RESULTS OF A PHASE II RANDOMIZED STUDY (ROMULUS) OF POLATUZUMAB VEDOTIN OR PINATUZUMAB VEDOTIN PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (NHL) Morschhauser, F., Flinn, I., Advani, R., Sehn, L., Kolibaba, K., Press, O., … Sharman, J. (2014). PRELIMINARY RESULTS OF A PHASE II RANDOMIZED STUDY (ROMULUS) OF POLATUZUMAB VEDOTIN OR PINATUZUMAB VEDOTIN PLUS RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (NHL). HAEMATOLOGICA, 99, 525.
  
• Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis Henderson, T. O., Parsons, S. K., Wroblewski, K. E., Chen, L., Hong, F., Smith, S. M., … Evens, A. M. (2018). Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. CANCER, 124(1), 136–44.
  
• Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. Evens, A. M., Advani, R. H., Helenowski, I. B., Fanale, M., Smith, S. M., Jovanovic, B. D., … Hamlin, P. A. (2018). Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2018790139.
  
• Circulating tumor DNA (ctDNA) in B-cell lymphoma Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2018). Circulating tumor DNA (ctDNA) in B-cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY, 182, 16–17.
  
• A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis Kim, S. J., Yoon, D. H., Jaccard, A., Chng, W. J., Lim, S. T., Hong, H., … Kim, W. S. (2016). A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. LANCET ONCOLOGY, 17(3), 389–400.
  
• Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Duncavage, E., Advani, R. H., Agosti, S., Foulis, P., Gibson, C., Kang, L., … Wilson, C. (2016). Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 140(11), 1228–30.
  
• End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making Melani, C., Advani, R., Roschewski, M., Walters, K. M., Chen, C. C., Baratto, L., … Wilson, W. H. (2018). End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making. HAEMATOLOGICA, 103(8), 1337–44.
  
• Prognostic Factors and Patterns of Failure in Advanced Stage Hodgkin Lymphoma Treated with Stanford V and Radiation Therapy Moding, E. J., Advani, R. H., Rosenberg, S. A., & Hoppe, R. T. (2018). Prognostic Factors and Patterns of Failure in Advanced Stage Hodgkin Lymphoma Treated with Stanford V and Radiation Therapy. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 102(3), S189–S190.
  
• The Outcomes of Patients with Unfavorable Stage I-II Classic Hodgkin Lymphoma Treated with Stanford V Chemotherapy and Limited Irradiation Weil, C., Qian, Y., Von Eyben, R., Daadi, S. E., Corbelli, K. S., Rosenberg, S. A., … Hoppe, R. T. (2018). The Outcomes of Patients with Unfavorable Stage I-II Classic Hodgkin Lymphoma Treated with Stanford V Chemotherapy and Limited Irradiation. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 102(3), S189.
  
• Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation Kharfan-Dabaja, M. A., Kumar, A., Ayala, E., Hamadani, M., Reimer, P., Gisselbrecht, C., … Savani, B. N. (2017). Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 23(11), 1826–38.
  
• Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia Thomas, S. K., Harb, W. A., Beck, J. T., Nashat, G., Palomba, M. L., Ansell, S. M., … Agrawal, S. (2015). Preliminary Results from a Phase 1/2, Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom's Macroglobulinemia. BLOOD, 126(23).
  
• Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up Wang, M., Rule, S. A., Martin, P., Goy, A., Auer, R., Kahl, B. S., … Blum, K. A. (2012). Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up. BLOOD, 120(21).
  
• Reply to J. Wang et al. Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., … Alizadeh, A. A. (2019). Reply to J. Wang et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1801907.
  
• A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicullar Lymphoma (FL) from in E2408 Hong, F., Evens, A. M., Novotny, P. J., Habermann, T. M., Advani, R. H., Gascoyne, R. D., … Thanarajasingam, G. (2018). A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicullar Lymphoma (FL) from in E2408. BLOOD, 132.
  
• Phase I trial of SNS-314, a novel selective inhibitor of Aurora kinases A, B, and C, in advanced solid tumor patients Robert, F., Hurwitz, H., Uronis, H., Verschraegen, C., Advani, R., Chen, A., … Evanchik, M. (2008). Phase I trial of SNS-314, a novel selective inhibitor of Aurora kinases A, B, and C, in advanced solid tumor patients. EJC SUPPLEMENTS, 6(12), 91–92.
  
• DURABLE REMISSIONS WITH SGN-35 (BRENTUXIMAB VEDOTIN): UPDATED RESULTS OF A PHASE 2 STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (SALCL) Shustov, A., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., … Pro, B. (2011). DURABLE REMISSIONS WITH SGN-35 (BRENTUXIMAB VEDOTIN): UPDATED RESULTS OF A PHASE 2 STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (SALCL). ANNALS OF ONCOLOGY, 22, 125.
  
• UPDATED INTERIM RESULTS OF AN INTERNATIONAL, MULTICENTER, PHASE 2 STUDY OF IBRUTINIB (PCI-32765) IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA Rule, S., Wang, M., Martin, P., Auer, R., Kahl, B., Jurczak, W., … Blum, K. (2013). UPDATED INTERIM RESULTS OF AN INTERNATIONAL, MULTICENTER, PHASE 2 STUDY OF IBRUTINIB (PCI-32765) IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA. HAEMATOLOGICA, 98, 489.
  
• Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Shustov, A. R., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., … Pro, B. (2010). Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. BLOOD, 116(21), 423–24.
  
• Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma LaCasce, A. S., Bociek, G., Sawas, A., Caimi, P. F., Agura, E., Matous, J., … Advani, R. (2015). Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma. BLOOD, 126(23).
  
• Functional characterization of Rab14 GTPase and its role in membrane trafficking and vesicular transport Junutula, Advani, R. J., Peden, A. A., de Maziere, A., Klumperman, J., & Scheller, R. H. (2002). Functional characterization of Rab14 GTPase and its role in membrane trafficking and vesicular transport. MOLECULAR BIOLOGY OF THE CELL, 13, 227A–228A.
  
• Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis Chu, M. P., Brody, J., Kohrt, H. E., Frank, M. J., Khodadoust, M., Reddy, S., … Levy, R. (2015). Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis. BLOOD, 126(23).
  
• Treatment of poor prognosis AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC). Advani, R., Saba, H. I., Tallman, M., Rowe, J. M., Wiernik, P. H., Ramek, J., … Greenberg, P. (1997). Treatment of poor prognosis AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC). BLOOD, 90(10), 2260.
  
• Phase I/II trial of ISIS3521, an antisense inhibitor of PKC alpha, with carboplatin and paclitaxel in non-small cell lung cancer. Yuen, A., Halsey, J., Lum, B., Fisher, G., Advani, R., Geary, R., … Sikic, B. I. (2000). Phase I/II trial of ISIS3521, an antisense inhibitor of PKC alpha, with carboplatin and paclitaxel in non-small cell lung cancer. CLINICAL CANCER RESEARCH, 6, 4572S.
  
• Novel Approaches in Waldenstrom Macroglobulinemia. Spinner, M. A., Varma, G., & Advani, R. H. (2018). Novel Approaches in Waldenstrom Macroglobulinemia. Hematology/Oncology Clinics of North America, 32(5), 875–90.
  
• Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1+Arm 2 Results from a Multicenter, Open-Label Phase 2 Study Fowler, N., Nastoupil, L., de Vos, S., Knapp, M., Flinn, I. W., Chen, R. W., … Palomba, M. L. (2016). Ibrutinib Combined with Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Arm 1+Arm 2 Results from a Multicenter, Open-Label Phase 2 Study. BLOOD, 128(22).
  
• Molecular Basis of Ibrutinib Resistance in Waldenstrom's Macroglobulinemia Xu, L., Tsakmaklis, N., Yang, G., Chen, J. G., Liu, X., Chen, J., … Treon, S. P. (2016). Molecular Basis of Ibrutinib Resistance in Waldenstrom's Macroglobulinemia. BLOOD, 128(22).
  
• SEQUENTIAL BRENTUXIMAB VEDOTIN AND ADRIAMYCIN, VINBLASTINE, AND DACARBAZINE FOR OLDER PATIENTS WITH UNTREATED HODGKIN LYMPHOMA: FINDINGS FROM A PHASE II WINDOW STUDY Evens, A. M., Hamlin, P. A., Nabhan, C., Advani, R., Fanale, M., Petrich, A., … Gordon, L. I. (2016). SEQUENTIAL BRENTUXIMAB VEDOTIN AND ADRIAMYCIN, VINBLASTINE, AND DACARBAZINE FOR OLDER PATIENTS WITH UNTREATED HODGKIN LYMPHOMA: FINDINGS FROM A PHASE II WINDOW STUDY. HAEMATOLOGICA, 101, 20.
  
• Treatment of angioimmunoblastic T-cell lymphoma (AILD) with cyclosporine. Advani, R., Horwitz, S., Harandi, A., Lee, M., Noy, A., Zelenetz, A. D., & Horning, S. J. (2003). Treatment of angioimmunoblastic T-cell lymphoma (AILD) with cyclosporine. BLOOD, 102(11), 180A.
  
• Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL). Forero-Torres, A., Moskowitz, C., Advani, R. H., Shah, B. D., Kostic, A., Albertson, T. M., … Fanale, M. A. (2014). Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL). JOURNAL OF CLINICAL ONCOLOGY, 32(15).
  
• CD30+expression in Peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-Cell Project Federico, M., Bellei, M., Luminari, S., Horwitz, S. M., Montoto, S., Zucca, E., … Vose, J. (2015). CD30+expression in Peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-Cell Project. JOURNAL OF CLINICAL ONCOLOGY, 33(15).
  
• Confirmation of the prognostic value of the EORTC/WHO classification of primary cutaneous B-cell lymphoma in the United States: The Stanford University experience Reddy, S. A., Kim, Y. H., Advani, R. H., & Hoppe, R. T. (2007). Confirmation of the prognostic value of the EORTC/WHO classification of primary cutaneous B-cell lymphoma in the United States: The Stanford University experience. JOURNAL OF CLINICAL ONCOLOGY, 25(18).
  
• Interim Positron Emission Tomography (PET) in Diffuse Large B-Cell Lymphoma: Independent Expert Nuclear Medicine Evaluation of ECOG 3404 Horning, S. J., Juweid, M. E., Schoder, H., Wiseman, G., McMillan, A., Swinnen, L. J., … Quon, A. (2008). Interim Positron Emission Tomography (PET) in Diffuse Large B-Cell Lymphoma: Independent Expert Nuclear Medicine Evaluation of ECOG 3404. BLOOD, 112(11), 145.
  
• CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma Advani, R., Flinn, I., Popplewell, L., Forero, A., Bartlett, N. L., Ghosh, N., … Smith, S. M. (2018). CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. NEW ENGLAND JOURNAL OF MEDICINE, 379(18), 1711–21.
  
• Longitudinal toxicity analysis with novel summary metrics of lenalidomide maintenance in follicular lymphoma in ECOG-ACRIN 2408. Thanarajasingam, G., Dueck, A. C., Novotny, P. J., Habermann, T. M., Advani, R. H., Gascoyne, R. D., … Hong, F. (2019). Longitudinal toxicity analysis with novel summary metrics of lenalidomide maintenance in follicular lymphoma in ECOG-ACRIN 2408. JOURNAL OF CLINICAL ONCOLOGY, 37(15).
  
• Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia Castillo, J., Allan, J., Siddiqi, T., Advani, R., Keezer, A., Gustine, J., … Treon, S. (2019). Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 19(10), E39–E40.
  
• Incidence and Outcomes of Rare T cell Lymphomas from the T Cell Project: Hepatosplenic, Enteropathy Associated and Peripheral Gamma Delta T cell Lymphomas. Foss, F. M., Horwitz, S. M., Civallero, M., Bellei, M., Marcheselli, L., Kim, W. S., … Federico, M. (2019). Incidence and Outcomes of Rare T cell Lymphomas from the T Cell Project: Hepatosplenic, Enteropathy Associated and Peripheral Gamma Delta T cell Lymphomas. American Journal of Hematology.
  
• Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease Advani, R., Maeda, L., Lavori, P., Quon, A., Hoppe, R., Breslin, S., … Horning, S. J. (2007). Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. JOURNAL OF CLINICAL ONCOLOGY, 25(25), 3902–7.
  
• Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma Characterization of Clinical Subset With Worse Outcome Woo, D. K., Jones, C. R., Vanoli-Storz, M. N., Kohler, S., Reddy, S., Advani, R., … Kim, Y. H. (2009). Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma Characterization of Clinical Subset With Worse Outcome. ARCHIVES OF DERMATOLOGY, 145(6), 667–74.
  
• Closing the gap: A comparison of observed versus expected survival in follicular lymphoma (FL) at Stanford University from 1960-2003 Tan, D., Rosenberg, S. A., Lavori, P., Sigal, B. M., Levy, R., Hoppe, R. T., … Horning, S. J. (2008). Closing the gap: A comparison of observed versus expected survival in follicular lymphoma (FL) at Stanford University from 1960-2003. JOURNAL OF CLINICAL ONCOLOGY, 26(15).
  
• Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia Treon, S. P., Tripsas, C. K., Ioakimidis, L., Warren, D., Patterson, C., Heffner, L., … Ghobrial, I. M. (2011). Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia. BLOOD, 118(21), 1273–74.
  
• IMMUNOTRANSPLANT FOR MANTLE CELL LYMPHOMA: PHASE I/II STUDY PRELIMINARY RESULTS Brody, J., Advani, R., Czerwinski, D., Negrin, R., & Levy, R. (2011). IMMUNOTRANSPLANT FOR MANTLE CELL LYMPHOMA: PHASE I/II STUDY PRELIMINARY RESULTS. Presented at the 11th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND: OXFORD UNIV PRESS.
  
• Phase II study of R-CHOP followed by Y-90-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern cooperative oncology group study E1499 Smith, M. R., Zhang, L., Gordon, L. I., Foran, J., Kahl, B., Gascoyne, R. D., … Horning, S. J. (2007). Phase II study of R-CHOP followed by Y-90-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern cooperative oncology group study E1499. BLOOD, 110(11), 121A–121A.
  
• A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies Fanale, M. A., Forero-Torres, A., Rosenblatt, J. D., Advani, R. H., Franklin, A. R., Kennedy, D. A., … Bartlett, N. L. (2012). A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies. CLINICAL CANCER RESEARCH, 18(1), 248–55.
  
• Optimal Therapy of Advanced Hodgkin Lymphoma Advani, R. (2011). Optimal Therapy of Advanced Hodgkin Lymphoma. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 310–16.
  
• How I treat nodular lymphocyte predominant Hodgkin lymphoma Advani, R. H., & Hoppe, R. T. (2013). How I treat nodular lymphocyte predominant Hodgkin lymphoma. BLOOD, 122(26), 4182–88.
  
• Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus Dimopoulos, M. A., Kastritis, E., Owen, R. G., Kyle, R. A., Landgren, O., Morra, E., … Treon, S. P. (2014). Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus. BLOOD, 124(9), 1404–11.
  
• Hodgkin Lymphoma, Version 2.2015 Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Bello, C. M., … Sundar, H. (2015). Hodgkin Lymphoma, Version 2.2015. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(5), 554–86.
  
• Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. Advani, R. H., Hong, F., Fisher, R. I., Bartlett, N. L., Robinson, K. S., Gascoyne, R. D., … Horning, S. J. (2015). Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. Journal of Clinical Oncology , 33(17), 1936–42.
  
• Breast Imaging in Women Previously Irradiated for Hodgkin Lymphoma. Horst, K. C., Fero, K. E., Hancock, S. L., Advani, R. H., Ikeda, D. M., Daniel, B., … Hoppe, R. T. (2016). Breast Imaging in Women Previously Irradiated for Hodgkin Lymphoma. American Journal of Clinical Oncology, 39(2), 114–19.
  
• Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma. Spinner, M. A., Varma, G., & Advani, R. H. (2018). Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma. British Journal of Haematology.
  
• ACR Appropriateness Criteria (R) Recurrent Hodgkin Lymphoma Winkfield, K. M., Advani, R. H., Ballas, L. K., Dabaja, B. S., Dhakal, S., Flowers, C. R., … Constine, L. S. (2016). ACR Appropriateness Criteria (R) Recurrent Hodgkin Lymphoma. ONCOLOGY-NEW YORK, 30(12), 1099–1108.
  
• A phase I trial of doxil, paclitaxel and valspodar (PSC 833). Advani, R., Fisher, G., Lum, B., Halsey, J., & Sikic, B. I. (2000). A phase I trial of doxil, paclitaxel and valspodar (PSC 833). CLINICAL CANCER RESEARCH, 6, 4504S.
  
• Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. Furman, R. R., Eradat, H. A., DiRienzo, C. G., Hofmeister, C. C., Hayman, S. R., Leonard, J. P., … Lin, T. S. (2017). Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. The Lancet. Haematology, 4(1), e24–e34.
  
• A humanized antibody against CD40 (SGN-40) is well tolerated and active in non-Hodgkin's lymphoma (NHL): Results of a phase I study. Forero-Torres, A., Furman, R. R., Rosenblatt, J. D., Younes, A., Harrop, K., Drachman, J. G., & Advani, R. (2006). A humanized antibody against CD40 (SGN-40) is well tolerated and active in non-Hodgkin's lymphoma (NHL): Results of a phase I study. JOURNAL OF CLINICAL ONCOLOGY, 24(18), 430S.
  
• IBRUTINIB FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL): EVALUATING THE CORRELATION BETWEEN PATIENT-REPORTED OUTCOMES AND DURABILITY OF RESPONSE IN A PHASE 2 STUDY Rule, S., Goy, A., Martin, P., Ramchandren, R., Alexeeva, J., Popat, R., … Wang, M. (2015). IBRUTINIB FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL): EVALUATING THE CORRELATION BETWEEN PATIENT-REPORTED OUTCOMES AND DURABILITY OF RESPONSE IN A PHASE 2 STUDY. VALUE IN HEALTH, 18(3), A300–A301.
  
• Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results. Advani, R. H., Flinn, I., Popplewell, L., Forero-Torres, A., Bartlett, N. L., Ghosh, N., … Smith, S. M. (2018). Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results. JOURNAL OF CLINICAL ONCOLOGY, 36(15).
  
• NCCN Guidelines (R) Insights Hodgkin Lymphoma, Version 1.2018 Featured Updates to the NCCN Guidelines Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Armand, P., … Ogba, N. (2018). NCCN Guidelines (R) Insights Hodgkin Lymphoma, Version 1.2018 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 16(3), 245–54.
  
• Prognostic value of LUGANO, EORTC, PERCIST and IHP criteria in patients with diffuse large B cell lymphoma based on 18F-FDG PET/CT Wu, F., Baratto, L., Minamimoto, R., Advani, R., Sabile, J., & Mittra, E. (2016). Prognostic value of LUGANO, EORTC, PERCIST and IHP criteria in patients with diffuse large B cell lymphoma based on 18F-FDG PET/CT. JOURNAL OF NUCLEAR MEDICINE, 57.
  
• CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. Advani, R., Flinn, I., Popplewell, L., Forero, A., Bartlett, N. L., Ghosh, N., … Smith, S. M. (2018). CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. The New England Journal of Medicine, 379(18), 1711–21.
  
• A phase I study with an expansion cohort of the combination of ipilimumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412). Diefenbach, C. S. M., Li, H., Kahl, B. S., Robertson, M. J., Cohen, J., Advani, R. H., … Ansell, S. M. (2015). A phase I study with an expansion cohort of the combination of ipilimumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412). JOURNAL OF CLINICAL ONCOLOGY, 33(15).
  
• Risk-adapted therapy for advanced-stage Hodgkin lymphoma. Spinner, M. A., & Advani, R. H. (2018). Risk-adapted therapy for advanced-stage Hodgkin lymphoma. Hematology. American Society of Hematology. Education Program, 2018(1), 200–206.
  
• Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level. Advani, R. H., Flinn, I., Sharman, J. P., Diefenbach, C. S. M., Kolibaba, K. S., Press, O. W., … Morschhauser, F. (2015). Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level. JOURNAL OF CLINICAL ONCOLOGY, 33(15).
  
• The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Park, S. I., Horwitz, S. M., Foss, F. M., Pinter-Brown, L. C., Carson, K. R., Rosen, S. T., … Shustov, A. R. (2019). The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer.
  
• A Phase 2 Clinical Trial of SGN-40 Monotherapy in Relapsed Diffuse Large B-Cell Lymphoma. Advani, R., De Vos, S., Ansell, S. M., Kahl, B., Cheson, B. D., Bartlett, N. L., … Forero-Torres, A. (2008). A Phase 2 Clinical Trial of SGN-40 Monotherapy in Relapsed Diffuse Large B-Cell Lymphoma. BLOOD, 112(11), 368.
  
• CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma. Advani, R., Volkmer, J.-P., & Chao, M. P. (2019). CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma. The New England Journal of Medicine, 380(5), 497–98.
  
• Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma Jin, M. C., Schroers-Martin, J. G., Kurtz, D. M., Buedts, L., Esfahani, M. S., Macaulay, C., … Alizadeh, A. A. (2018). Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma. BLOOD, 132.
  
• New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little? Spinner, M. A., Advani, R. H., Connors, J. M., Azzi, J., & Diefenbach, C. (2018). New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little? American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, 38, 626–36.
  
• The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+Peripheral T-Cell Lymphomas Horwitz, S. M., O'Connor, O. A., Pro, B., Illidge, T. M., Fanale, M. A., Advani, R. H., … Truemper, L. (2018). The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+Peripheral T-Cell Lymphomas. BLOOD, 132.
  
• The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study Park, S. I., Horwitz, S. M., Foss, F. M., Pinter-Brown, L. C., Carson, K. R., Rosen, S. T., … Shustov, A. R. (2019). The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. CANCER, 125(9), 1507–17.
  
• Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry. Lansigan, F., Horwitz, S. M., Pinter-Brown, L. C., Rosen, S. T., Pro, B., Hsi, E. D., … Foss, F. M. (2019). Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry. Acta Haematologica, 1–11.
  
• CD20-negative nodular lymphocyte-predominant Hodgkin lymphoma is enriched for variant patterns and shows aggressive clinical features Menke, J., Spinner, M., Shrestha, B., Advani, R., Natkunam, Y., & Gratzinger, D. (2019). CD20-negative nodular lymphocyte-predominant Hodgkin lymphoma is enriched for variant patterns and shows aggressive clinical features. LABORATORY INVESTIGATION, 99.
  
• CD20-negative nodular lymphocyte-predominant Hodgkin lymphoma is enriched for variant patterns and shows aggressive clinical features Menke, J., Spinner, M., Shrestha, B., Advani, R., Natkunam, Y., & Gratzinger, D. (2019). CD20-negative nodular lymphocyte-predominant Hodgkin lymphoma is enriched for variant patterns and shows aggressive clinical features. MODERN PATHOLOGY, 32.
  
• Stage I-II Nodular Lymphocyte-Predominant Hodgkin Lymphoma: a Multi-institutional Experience of Adult Patients by ILROG. Binkley, M. S., Rauf, M. S., Milgrom, S. A., Pinnix, C. C., Tsang, R. W., Dickinson, M., … Hoppe, R. T. (2020). Stage I-II Nodular Lymphocyte-Predominant Hodgkin Lymphoma: a Multi-institutional Experience of Adult Patients by ILROG. Blood.
  
• Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Wang, M. L., Blum, K. A., Martin, P., Goy, A., Auer, R., Kahl, B. S., … Rule, S. (2015). Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood, 126(6), 739–45.
  
• Improving care with portfolio of physician-led cancer quality measures at an academic center Porter, J., Smith, A. S., Winget, M., Rosenthal, E. L., Seshadri, S. B., Vetteth, Y., … Blayney, D. W. (2017). Improving care with portfolio of physician-led cancer quality measures at an academic center. JOURNAL OF CLINICAL ONCOLOGY, 35(8).
  
• POPULATION PHARMACOKINETICS OF MAGROLIMAB (5F9, HU5F9--G4) IN PATIENTS WITH SOLID TUMORS AND LYMPHOMAS. Agoram, B., Jin, C., Wang, B., Sikic, B., Advani, R., Chao, M., & Takimoto, C. (2020). POPULATION PHARMACOKINETICS OF MAGROLIMAB (5F9, HU5F9--G4) IN PATIENTS WITH SOLID TUMORS AND LYMPHOMAS. CLINICAL PHARMACOLOGY & THERAPEUTICS, 107, S85.
  
• Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing) Advani, R. H., Moskowitz, A. J., Bartlett, N. L., Vose, J. M., Ramchandren, R., Feldman, T. A., … Herrera, A. F. (2018). Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing). BLOOD, 132.
  
• SGN-40 shows evidence of activity in patients with relapsed non-Hodgkin lymphoma: Final results of a phase I dose-escalation study Advani, R., Forero-Torres, A., Furman, R. R., Rosenblatt, J. D., Younes, A., Harrop, K., … Drachman, J. G. (2008). SGN-40 shows evidence of activity in patients with relapsed non-Hodgkin lymphoma: Final results of a phase I dose-escalation study. ANNALS OF ONCOLOGY, 19, 115.
  
• Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K-delta,gamma Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab Casulo, C., Sancho, J.-M., Van Eygen, K., de Vos, S., Mercadal, S., Johnson, R. J., … Goy, A. (2016). Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K-delta,gamma Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab. BLOOD, 128(22).
  
• Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study Fowler, N., Nastoupil, L., de Vos, S., Knapp, M., Flinn, I. W., Chen, R., … Palomba, M. L. (2015). Ibrutinib Plus Rituximab in Treatment-Naive Patients with Follicular Lymphoma: Results from a Multicenter, Phase 2 Study. BLOOD, 126(23).
  
• Multicenter study for comparison of FLT and FDG PET/CT for early interim therapy monitoring of diffuse large B-cell lymphoma Minamimoto, R., Vose, J., Advani, R., Fayad, L., Macapinlac, H., Meza, J., … Quon, A. (2014). Multicenter study for comparison of FLT and FDG PET/CT for early interim therapy monitoring of diffuse large B-cell lymphoma. JOURNAL OF NUCLEAR MEDICINE, 55.
  
• Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update Advani, R. H., Shustov, A. R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., … Pro, B. (2011). Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update. BLOOD, 118(21), 204.
  
• The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase 1 Studies Burger, J. A., O'Brien, S., Fowler, N., Advani, R., Sharman, J. P., Furman, R. R., … Blum, K. A. (2010). The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase 1 Studies. BLOOD, 116(21), 32.
  
• Brentuximab vedotin (SGN-35) treatment in relapsed CD30-positive Hodgkin's lymphoma patients following allogeneic stem cell transplant: a multi-centre case series Gopal, A. K., Ramchandren, R., Berryman, R. B., Advani, R. H., Chen, R., Smith, S., … O'Connor, O. A. (2011). Brentuximab vedotin (SGN-35) treatment in relapsed CD30-positive Hodgkin's lymphoma patients following allogeneic stem cell transplant: a multi-centre case series. BONE MARROW TRANSPLANTATION, 46, S36.
  
• Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy Moding, E. J., Advani, R., Rosenberg, S. A., & Hoppe, R. T. (2018). Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy. RADIOTHERAPY AND ONCOLOGY, 129(3), 507–12.
  
• Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma Spinner, M. A., Varma, G., & Advani, R. H. (2019). Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma. BRITISH JOURNAL OF HAEMATOLOGY, 184(1), 17–29.
  
• Subsequent primary malignancies (SPMs) after diffuse large B-cell lymphoma (DLBCL) in the modern treatment era. Keegan, T. H. M., Clarke, C. A., Rosenberg, A. S., Advani, R. H., Jonas, B. A., Flowers, C., & Tao, L. (2016). Subsequent primary malignancies (SPMs) after diffuse large B-cell lymphoma (DLBCL) in the modern treatment era. JOURNAL OF CLINICAL ONCOLOGY, 34(15).
  
• PHASE 1 STUDY OF NAVITOCLAX (ABT-263) PLUS RITUXIMAB IN CD20-POSITIVE LYMPHOID MALIGNANCIES Roberts, W., Advani, R., Kahl, B., Persky, D., Xiong, H., Cui, Y., … Humerickhouse, R. (2010). PHASE 1 STUDY OF NAVITOCLAX (ABT-263) PLUS RITUXIMAB IN CD20-POSITIVE LYMPHOID MALIGNANCIES. HAEMATOLOGICA, 95, 371.
  
• Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies. Alizadeh, A. A., & Advani, R. H. (2008). Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies. Clinical Advances in Hematology & Oncology : H&O, 6(12), 899–909.
  
• Targeting CD40 in Waldenstrom's Macroglobulinemia Lee, M., & Advani, R. (2009). Targeting CD40 in Waldenstrom's Macroglobulinemia. CLINICAL LYMPHOMA & MYELOMA, 9(1), 87–89.
  
• Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP) Gratzinger, D., Advani, R., Zhao, S., Talreja, N., Tibshirani, R. J., Shyam, R., … Natkunam, Y. (2010). Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). BRITISH JOURNAL OF HAEMATOLOGY, 148(2), 235–44.
  
• Navitoclax (ABT-263) Plus Rituximab: Interim Results of a Phase 1 Study In Patients with CD20-Positive Lymphoid Malignancies Kahl, B., Roberts, A. W., Seymour, J. F., Advani, R. H., Persky, D. O., Yang, J., … Humerickhouse, R. (2010). Navitoclax (ABT-263) Plus Rituximab: Interim Results of a Phase 1 Study In Patients with CD20-Positive Lymphoid Malignancies. BLOOD, 116(21), 1608–.
  
• Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis Evens, A. M., Advani, R., Lossos, I. S., Press, O. W., Vose, J. M., Hernandez-Ilizaliturri, F. J., … Bartlett, N. L. (2011). Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis. BLOOD, 118(21), 45–46.
  
• Denileukin diftitox (ONTAK) plus CHOP chemotherapy in patients with peripheral T-Cell lymphomas (PTCL), the CONCEPT trial Foss, F., Sjak-Shie, N., Goy, A., Jacobsen, E., Advani, R., Smith, M., … Acosta, M. (2007). Denileukin diftitox (ONTAK) plus CHOP chemotherapy in patients with peripheral T-Cell lymphomas (PTCL), the CONCEPT trial. BLOOD, 110(11), 1011A–1011A.
  
• Prognostic factors in primary cutaneous anaplastic large cell lymphoma: Clinical and molecular characterization of a subset with worse outcome Woo, D., Jones, C., Vanoli-Storz, M., Kohler, S., Reddy, S., Advani, R., … Kim, Y. (2007). Prognostic factors in primary cutaneous anaplastic large cell lymphoma: Clinical and molecular characterization of a subset with worse outcome. BLOOD, 110(11), 1045A–1045A.
  
• Mid-treatment Metabolic Tumor Volume Predicts Progression and Death among Patients with Hodgkin's Disease Tseng, D., Rachakonda, L. P., Su, Z., Advani, R., Horning, S., Rosenberg, S. A., … Tran, P. T. (2010). Mid-treatment Metabolic Tumor Volume Predicts Progression and Death among Patients with Hodgkin's Disease. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S546–S547.
  
• Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: Results of WMCTG trial 03-248 Treon, S. P., Hunter, Z. R., Matous, J., Joyce, R. M., Mannion, B., Advani, R., … Badros, A. (2007). Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: Results of WMCTG trial 03-248. CLINICAL CANCER RESEARCH, 13(11), 3320–25.
  
• Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. Evens, A. M., Advani, R., Press, O. W., Lossos, I. S., Vose, J. M., Hernandez-Ilizaliturri, F. J., … Bartlett, N. L. (2013). Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. Journal of Clinical Oncology , 31(32), 4132–39.
  
• Non-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., … Dwyer, M. A. (2012). Non-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(12), 1487–98.
  
• Non-Hodgkin's lymphomas, version 1.2013. Zelenetz, A. D., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., Bartlett, N., … Naganuma, M. (2013). Non-Hodgkin's lymphomas, version 1.2013. Journal of the National Comprehensive Cancer Network , 11(3), 257–272.
  
• Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Ganjoo, K., Hong, F., Horning, S. J., Gascoyne, R. D., Natkunam, Y., Swinnen, L. J., … Advani, R. H. (2014). Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leukemia & Lymphoma, 55(4), 768–72.
  
• Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies Bartlett, N. L., Chen, R., Fanale, M. A., Brice, P., Gopal, A., Smith, S. E., … Forero-Torres, A. (2014). Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. JOURNAL OF HEMATOLOGY & ONCOLOGY, 7.
  
• ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma Ha, C. S., Hodgson, D. C., Advani, R., Dabaja, B. S., Dhakal, S., Flowers, C. R., … Constine, L. S. (2014). ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma. JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY, 11(11), 1026–33.
  
• Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). Wagner, L. I., Zhao, F., Hong, F., Williams, M. E., Gascoyne, R. D., Krauss, J. C., … Kahl, B. S. (2015). Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). Journal of Clinical Oncology , 33(7), 740–48.
  
• Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies Han, T. H., Chen, R., Advani, R., Berryman, R. B., Smith, S. E., Forero-Torres, A., … Engert, A. (2013). Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 72(1), 241–49.
  
• Postibrutinib outcomes in patients with mantle cell lymphoma Martin, P., Maddocks, K., Leonard, J. P., Ruan, J., Goy, A., Wagner-Johnston, N., … Blum, K. A. (2016). Postibrutinib outcomes in patients with mantle cell lymphoma. BLOOD, 127(12), 1559–63.
  
• A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy Binkley, M. S., Hiniker, S. M., Wu, S., Natkunam, Y., Mittra, E. S., Advani, R. H., & Hoppe, R. T. (2016). A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. LEUKEMIA & LYMPHOMA, 57(3), 604–8.
  
• Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center Porter, J. B. (2017). Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center. Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center, 13(8), e673–e682.
  
• Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium Stevens, W. B. C., Mendeville, M., Redd, R., Clear, A. J., Bladergroen, R., Calaminici, M., … de Jong, D. (2017). Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. HAEMATOLOGICA, 102(8), 1413–23.
  
• New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little? Spinner, M. A., Advani, R. H., Connors, J. M., Azzi, J., & Diefenbach, C. (2018). New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little? American Society of Clinical Oncology Education Book, 38.
  
• Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., … Shustov, A. (2017). Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. BLOOD, 130(25), 2709–17.
  
• Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05) Swinnen, L. J., O'Neill, A., Imus, P. H., Gujar, S., Schiff, D., Kleinberg, L. R., … Grossman, S. A. (2018). Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05). ONCOTARGET, 9(1), 766–73.
  
• Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma Kohrt, H. E., Chu, J., Brody, J., Czerwinski, D. K., Chester, C., Sadaram, M., … Levy, R. (2014). Dose-Escalated, Intratumoral TLR9 Agonist and Low-Dose Radiation Induce Abscopal Effects in Follicular Lymphoma. BLOOD, 124(21).
  
• In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs Tefferi, A., Rajkumar, S. V., Gertz, M. A., Kyle, R. A., Kantarjian, H., Allison, J., … Wiernik, P. H. (2015). In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. MAYO CLINIC PROCEEDINGS, 90(8), 996–1000.
  
• Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma Kurtz, D. M., Scherer, F., Newman, A. M., Craig, A., Jin, M., Stehr, H., … Alizadeh, A. A. (2016). Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma. BLOOD, 128(22).
  
• Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenstrom macroglobulinemia Castillo, J. J., Gustine, J. N., Meid, K., Dubeau, T. E., Xu, L., Yang, G., … Treon, S. P. (2018). Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenstrom macroglobulinemia. HAEMATOLOGICA, 103(10), E466–E468.
  
• Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy. Moding, E. J., Advani, R., Rosenberg, S. A., & Hoppe, R. T. (2018). Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy. Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology, 129(3), 507–12.
  
• Brentuximab Vedotin Plus Chemotherapy in North American Patients with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. Ramchandren, R., Advani, R. H., Ansell, S. M., Bartlett, N. L., Chen, R., Connors, J. M., … Straus, D. J. (2019). Brentuximab Vedotin Plus Chemotherapy in North American Patients with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
  
• Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers Kothari, S. K., Li, S., Medeiros, L. J., Ayers, E. C., Landsburg, D. J., Bond, D. A., … Torka, P. (2018). Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers. BLOOD, 132.
  
• Phase I trial of SNS-595 in patients with advanced malignancies. Advani, R., Gordon, M., Hurwitz, H., Mendelson, D., Wakelee, H., Ebbinghaus, S., … Adelman, D. (2005). Phase I trial of SNS-595 in patients with advanced malignancies. JOURNAL OF CLINICAL ONCOLOGY, 23(16), 159S.
  
• Phase II Study of Rituximab Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System Lymphoma (PCNSL)[E1F05] Swinnen, L. J., O'Neill, A., Imus, P. H., Gujar, S., Schiff, D., Kleinberg, L., … Grossman, S. (2015). Phase II Study of Rituximab Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System Lymphoma (PCNSL)[E1F05]. BLOOD, 126(23).
  
• Immunotransplant for mantle cell lymphoma: Phase I/II study preliminary results. Brody, J., Advani, R., Weng, W., Czerwinski, D., Alizadeh, A. A., Kohrt, H. E., … Levy, R. (2011). Immunotransplant for mantle cell lymphoma: Phase I/II study preliminary results. JOURNAL OF CLINICAL ONCOLOGY, 29(15).
  
• Phase II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer: Updated survival and time to progression data. Yuen, A., Halsey, J., Fisher, G., Advani, R., Moore, M., Saleh, M., … Sikic, B. (2001). Phase II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer: Updated survival and time to progression data. CLINICAL CANCER RESEARCH, 7(11), 3681S.
  
• Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. Carreau, N. A., Armand, P., Merryman, R. W., Advani, R. H., Spinner, M. A., Herrera, A. F., … Diefenbach, C. (2020). Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. British Journal of Haematology.
  
• Hodgkin disease/lymphoma. Hoppe, R. T., Advani, R. H., Ambinder, R. F., Bierman, P. J., Bloomfield, C. D., Blum, K., … Zelenetz, A. D. (2008). Hodgkin disease/lymphoma. Journal of the National Comprehensive Cancer Network , 6(6), 594–622.
  
• Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). (1999). Blood, 93.
  
• OUTCOME OF LYMPHOMA DURING PREGNANCY: AN INDIVIDUALIZED THERAPEUTIC APPROACH RESULTS IN EXCELLENT PATIENT OUTCOMES AND MINIMAL OBSTETRIC OR FETAL COMPLICATIONS YARBER, J. L., Otis, S. A., Robinson, B. K., Gordon, L. I., Winter, J. N., Advani, R. H., & Evens, A. M. (2011). OUTCOME OF LYMPHOMA DURING PREGNANCY: AN INDIVIDUALIZED THERAPEUTIC APPROACH RESULTS IN EXCELLENT PATIENT OUTCOMES AND MINIMAL OBSTETRIC OR FETAL COMPLICATIONS. Presented at the 11th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND: OXFORD UNIV PRESS.
  
• Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Preliminary results of a phase II trial of intra-tumoral CpG 7909 Brody, J., Ai, W. Z., Czerwinski, D., Advani, R., Horning, S. J., Ganjoo, K. N., & Levy, R. (2008). Clinical and immunologic responses to a novel in situ lymphoma vaccine maneuver: Preliminary results of a phase II trial of intra-tumoral CpG 7909. JOURNAL OF CLINICAL ONCOLOGY, 26(15).
  
• Phase II study of rituximab plus CHOP followed by Y-90-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499). Smith, M. R., Chen, H., Gordon, L., Foran, J., Kahl, B., Advani, R., … Horning, S. J. (2006). Phase II study of rituximab plus CHOP followed by Y-90-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499). JOURNAL OF CLINICAL ONCOLOGY, 24(18), 422S–422S.
  
• A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay. Pollyea, D. A., Smith, S., Fowler, N., Boyd, T. E., Smith, A. M., Sirisawad, M., … Advani, R. (2009). A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay. BLOOD, 114(22), 1430–30.
  
• Hodgkin lymphoma. Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Bello, C. M., Bierman, P. J., … Yahalom, J. (2011). Hodgkin lymphoma. Journal of the National Comprehensive Cancer Network , 9(9), 1020–58.
  
• Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma Rubenstein, J. L., Li, J., Chen, L., Advani, R., Drappatz, J., Gerstner, E., … Damon, L. E. (2013). Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. BLOOD, 121(5), 745–51.
  
• Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Tan, D., Horning, S. J., Hoppe, R. T., Levy, R., Rosenberg, S. A., Sigal, B. M., … Advani, R. H. (2013). Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood, 122(6), 981–87.
  
• Efficacy of Abbreviated Stanford V Chemotherapy and Involved Field Radiotherapy in Early Stage Hodgkin's Disease: Mature Results of the G4 Trial. Advani, R. H., Hoppe, R. T., Baer, D. M., Mason, J., Rosenberg, S. A., & Horning, S. J. (2009). Efficacy of Abbreviated Stanford V Chemotherapy and Involved Field Radiotherapy in Early Stage Hodgkin's Disease: Mature Results of the G4 Trial. BLOOD, 114(22), 666–67.
  
• Targeted Therapy in Relapsed Classical Hodgkin Lymphoma Dinner, S., & Advani, R. (2013). Targeted Therapy in Relapsed Classical Hodgkin Lymphoma. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(8), 968–76.
  
• A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study Foss, F. M., Sjak-Shie, N., Goy, A., Jacobsen, E., Advani, R., Smith, M. R., … Bolejack, V. (2013). A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. LEUKEMIA & LYMPHOMA, 54(7), 1373–79.
  
• Non-Hodgkin's lymphomas, version 2.2014. Zelenetz, A. D., Gordon, L. I., Wierda, W. G., Abramson, J. S., Advani, R. H., Andreadis, C. B., … Sundar, H. (2014). Non-Hodgkin's lymphomas, version 2.2014. Journal of the National Comprehensive Cancer Network , 12(6), 916–46.
  
• A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma Foss, F., Advani, R., Duvic, M., Hymes, K. B., Intragumtornchai, T., Lekhakula, A., … Pohlman, B. (2015). A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY, 168(6), 811–19.
  
• ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma. Dabaja, B. S., Advani, R., Hodgson, D. C., Dhakal, S., Flowers, C. R., Ha, C. S., … Constine, L. S. (2015). ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma. American Journal of Clinical Oncology, 38(6), 610–20.
  
• Intra-CSF rituximab for lymhomatous meningitis - Reply Rubenstein, J., Abrey, L., Advani, R., Shuman, M., Tsai, T., & O'Brien, J. (2007). Intra-CSF rituximab for lymhomatous meningitis - Reply. JOURNAL OF CLINICAL ONCOLOGY, 25(28), 4509–11.
  
• Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma. Matthews, J. M., Bhatt, S., Patricelli, M. P., Nomanbhoy, T. K., Jiang, X., Natkunam, Y., … Lossos, I. S. (2016). Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma. Blood, 128(2), 239–48.
  
• A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. Advani, R. H., Ansell, S. M., Lechowicz, M. J., Beaven, A. W., Loberiza, F., Carson, K. R., … M Vose, J. (2016). A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. British Journal of Haematology, 172(4), 535–44.
  
• Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom Macroglobulinaemia Xu, L., Hunter, Z. R., Tsakmaklis, N., Cao, Y., Yang, G., Chen, J., … Treon, S. P. (2016). Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom Macroglobulinaemia. BRITISH JOURNAL OF HAEMATOLOGY, 172(5), 735–44.
  
• Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management. Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management. (2016). British Journal of Haematology.
  
• Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CT. Lynch, R. C., & Advani, R. H. (2016). Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CT. American Society of Clinical Oncology Educational Book / ASCO. American Society of Clinical Oncology. Meeting, 35, e376–85.
  
• ACR Appropriateness Criteria (R) Hodgkin Lymphoma-Favorable Prognosis Stage I and II Dhakal, S., Advani, R., Ballas, L. K., Dabaja, B. S., Flowers, C. R., Ha, C. S., … Constine, L. S. (2016). ACR Appropriateness Criteria (R) Hodgkin Lymphoma-Favorable Prognosis Stage I and II. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 39(6), 535–44.
  
• Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up Wang, M., Rule, S. A., Martin, P., Goy, A., Auer, R., Kahl, B. S., … Blum, K. A. (2012). Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up. BLOOD, 120(21).
  
• BIOMARKERS IN RELAPSED/REFRACTORY DLBCL AND FL PATIENTS TREATED WITH POLATUZUMAB VEDOTIN: RESULTS FROM THE PHASE II CLINICAL TRIAL (ROMULUS) Penuel, E., Mundt, K., Bourgon, R., Sumiyoshi, T., Flinn, I., Press, O., … Hirata, J. (2016). BIOMARKERS IN RELAPSED/REFRACTORY DLBCL AND FL PATIENTS TREATED WITH POLATUZUMAB VEDOTIN: RESULTS FROM THE PHASE II CLINICAL TRIAL (ROMULUS). HAEMATOLOGICA, 101, 578.
  
• MicroRNA Are Useful Biomarkers for Prediction of Response to Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma Alencar, A. J., Malumbres, R., Advani, R., Talreja, N., Shyam, R., Briones, J., … Lossos, I. S. (2009). MicroRNA Are Useful Biomarkers for Prediction of Response to Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma. BLOOD, 114(22), 258–59.
  
• KLHL6 Is Preferentially Expressed in Germinal Center-Derived B-Cell Lymphomas Kunder, C. A., Roncador, G., Advani, R. H., Gualco, G., Bacchi, C. E., Sabile, J. M., … Natkunam, Y. (2017). KLHL6 Is Preferentially Expressed in Germinal Center-Derived B-Cell Lymphomas. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 148(6), 465–76.
  
• Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network Federico, M., Bellei, M., Marcheselli, L., Schwartz, M., Manni, M., Tarantino, V., … Advani, R. H. (2018). Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. BRITISH JOURNAL OF HAEMATOLOGY, 181(6), 760–69.
  
• The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project Bellei, M., Foss, F. M., Shustov, A. R., Horwitz, S. M., Marcheselli, L., Kim, W. S., … Federico, M. (2018). The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. HAEMATOLOGICA, 103(7), 1191–97.
  
• Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome Kritharis, A., Kanakry, J. A., Sehn, L. H., Feldman, T., Kroll, A., Gascoyne, R. D., … Evens, A. M. (2014). Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome. BLOOD, 124(21).
  
• Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). Morschhauser, F., Flinn, I., Advani, R. H., Sehn, L. H., Kolibaba, K. S., Press, O. W., … Sharman, J. P. (2014). Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). JOURNAL OF CLINICAL ONCOLOGY, 32(15).
  
• A Phase II Study(A)over-cap of Sequential Pembrolizumab (PEM)(A)over-cap Followed(A)over-cap By AVD for Frontline Treatment(A)over-cap of Classical Hodgkin Lymphoma (CHL): Quantifying Response Following(A)over-cap PEM Monotherapy(A)over-cap with FDG-PLT-Derived Metabolic Tumor Volume and Total Lesion Glycolysis Savas, H., Allen, P., Evens, A. M., Pro, B., Dillehay, G., Rademaker, A., … Winter, J. N. (2018). A Phase II Study(A)over-cap of Sequential Pembrolizumab (PEM)(A)over-cap Followed(A)over-cap By AVD for Frontline Treatment(A)over-cap of Classical Hodgkin Lymphoma (CHL): Quantifying Response Following(A)over-cap PEM Monotherapy(A)over-cap with FDG-PLT-Derived Metabolic Tumor Volume and Total Lesion Glycolysis. BLOOD, 132.
  
• Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy Bannerji, R., Brown, J. R., Advani, R. H., Arnason, J., O'Brien, S. M., Allan, J. N., … Brownstein, C. (2016). Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy. BLOOD, 128(22).
  
• Patient Characteristics and Initial Treatment Patterns in the United States for the Most Common Subtypes of Peripheral T-Cell Lymphoma (PTCL) Pinter-Brown, L., Foss, F. M., Carson, K. R., Horwitz, S. M., Rosen, S. T., Pro, B., … Park, S. I. (2014). Patient Characteristics and Initial Treatment Patterns in the United States for the Most Common Subtypes of Peripheral T-Cell Lymphoma (PTCL). BLOOD, 124(21).
  
• BRENTUXIMAB VEDOTIN IN COMBINATION WITH CHP IN PATIENTS (PTS) WITH NEWLY-DIAGNOSED CD30+PERIPHERAL T-CELL LYMPHOMAS (PTCL): 2-YEAR FOLLOW-UP Fanale, M. A., Horwitz, S. M., Forero-Torres, A., Bartlett, N. L., Advani, R. H., Pro, B., … Shustov, A. R. (2014). BRENTUXIMAB VEDOTIN IN COMBINATION WITH CHP IN PATIENTS (PTS) WITH NEWLY-DIAGNOSED CD30+PERIPHERAL T-CELL LYMPHOMAS (PTCL): 2-YEAR FOLLOW-UP. ANNALS OF ONCOLOGY, 25.
  
• A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402). Witzig, T. E., Hong, F., Micallef, I. N., Gascoyne, R. D., Dogan, A., Wagner, H., … Horning, S. J. (2012). A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402). BLOOD, 120(21).
  
• The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma Fowler, N. H., Advani, R. H., Sharman, J., Smith, S. M., McGreivy, J., Kunkel, L., … Boyd, T. E. (2012). The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma. BLOOD, 120(21).
  
• Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma Pohlman, B., Advani, R., Duvic, M., Hymes, K. B., Intragumtornchai, T., Lekhakula, A., … Foss, F. M. (2009). Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma. BLOOD, 114(22), 379.
  
• Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma Reply Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2019). Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma Reply. JOURNAL OF CLINICAL ONCOLOGY, 37(9), 755-+.
  
• B-Cell Lymphomas, Version 3.2019 Featured Updates to the NCCN Guidelines Zelenetz, A. D., Gordon, L. I., Abramson, J. S., Advani, R. H., Bartlett, N. L., Caimi, P. F., … Sundar, H. (2019). B-Cell Lymphomas, Version 3.2019 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 17(6), 651–61.